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Hodgkin lymphoma (HL) is a hematological malignancy. The malignant cells 
in HL, the Hodgkin and Reed Sternberg (HRS) cells, comprise only a minority 
of the entire tumor mass while infiltrating inflammatory cells constitute the 
vast majority of the tumor mass. HRS cells were reported to express CD137 
ectopically but the function(s) of CD137 in the pathogenesis of HL remained 
unidentified. CD137 is a potent co-stimulatory molecule expressed by 
activated T cells. Upon ligation by CD137 ligand (CD137L) which is mainly 
expressed by antigen presenting cells (APC), CD137 signalling enhances T 
cell activity. This study shows that ectopic CD137 expression on HRS cells 
reduces IFN-γ release from T cells by downregulating CD137L expression on 
HRS cells. The IFN-γ suppression due to ectopic CD137 expression can be 
reversed by neutralizing CD137 with antibodies or by knocking down CD137 
with siRNA. The downregulation of CD137L is not due to a reduction of de 
novo synthesis of CD137L but due to an increased CD137L turnover. When 
CD137 binds to CD137L, the CD137-CD137L complex will be internalized, 
and hence the surface CD137L levels available for T cell co-stimulation are 
reduced. Ectopic CD137 also gets transferred from HRS cells to surrounding 
cells including B cells and monocytes and leads to the downregulation of 
CD137L on monocytes. The CD137L downregulation on monocytes results in 
a lower T cell co-stimulation and a reduction of IFN-γ release from T cells. In 
addition, this study finds that ectopic CD137 on HRS cells might induce 
signalling into HRS cells but the benefits that HRS cells may gain from this 
signalling are yet to be identified. In conclusion, this study provides new 
 viii 
insights into the immune escape mechanism of HL, and opens new research 
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CHAPTER 1 INTRODUCTION 
Malignant disease is one of the most common causes of human mortality. 
Despite all the efforts in improving patients’ prognosis, cancer remains one of 
the deadliest diseases. The bottleneck which we face in cancer treatment is 
probably due to restricted knowledge on cancer biology and its pathogenesis.  
 
Using Hodgkin lymphoma as an example, there has been little breakthrough in 
the understanding of its pathogenesis since Hodgkin and Reed Sternberg cells 
were reported to be originated from B cells in the 90's (Kuppers et al., 1994). 
Lacking of knowledge has restricted the effort to improve treatments and 
reduce side effects that accompany the usage of conventional treatment. The 
primary strategy of Hodgkin lymphoma treatment is mainly comprised of 
chemotherapy and radiotherapy. These kind of therapeutic methods have 
significantly prolonged the survival rate of Hodgkin lymphoma patients, 
nonetheless these therapies produce substantial toxicities as a side effect and 
still result in a high frequency of relapse in the long term (Evens et al., 2008; 
Re et al., 2005). 
 
Thus the motivation of this study is to find out a novel mechanism which 
could further explain the pathogenesis of Hodgkin lymphoma. The new 
knowledge is expected to lead to a new immunotherapy approach and 
ultimately improve the management for Hodgkin lymphoma in patients.  
 
In this section, the current knowledge of Hodgkin lymphoma, its pathogenesis 
and roles of microenvironment in sustaining its growth will be discussed. 
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Apart from that, the functionality of CD137 and CD137L and their 
involvement in the development of various diseases will also be discussed. 
 
1.1 Hodgkin Lymphoma 
Hodgkin lymphoma (HL) is a type of hematological malignancy which usually 
affects lymph nodes of the patient. It was first characterized by Thomas 
Hodgkin in 1832 (Hodgkin, 1832). Malignant growth of HL is commonly 
found at cervical of supraclavicular region and often coupled with other 
clinical symptoms like cyclical fever, night sweat and loss of body weight. 
Due to the similarity of these symptoms with viral infection and other 
malignancies, histology is necessary to confirm the diagnosis of HL 
(Townsend and Linch, 2012).  
 
Unlike other types of solid tumors, HL is mainly comprised of infiltrating 
inflammatory cells, e.g. histiocytes (old name for tissue macrophages), 
lymphocytes, eosinophils, etc. The malignant cells in HL, multinucleated 
Reed-Sternberg (RS) cells and their mononucleated variant Hodgkin cells 
usually comprise as little as 1% of the tumor mass (Re et al., 2005). HRS cells 
visually appear as a symmetrical bi-nucleated cell resembles an “Owl’s eye” 
(Mani and Jaffe, 2009) which is very characteristic and important for the 
diagnosis of HL. Hodgkin cells and Reed-Sternberg cells have a similar 
immunophenotype (Abe et al., 1988) and are often combined and called 
Hodgkin and Reed Sternberg (HRS) cells. Studies found that the majority of 
the HRS cells are derived from germinal center (GC) B cells which produce 
no functional BCR after undergoing the somatic hypermutation process. Under 
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physiological condition, these GC B cells which do not produce highly 
specific antibodies will be removed quickly in the GC via apoptosis but pre-
cursor of HRS cells are resistant to apoptosis and transform into HRS cells 
(Kuppers and Rajewsky, 1998). 
 
1.1.1 Etiology and pathophysiology 
HL is classified into 2 major subtypes, classical HL and nodular lymphocyte 
predominant Hodgkin lymphoma (NLPHL). NLPHL is not recognized as 
classical HL because the malignant cells in NLPHL, lymphocytic and 
histiocytic (L&H) cells, have low or null expression of classical HRS cell 
markers (CD30, CD15, bcl-2) but are positive for CD20 which is a B cell 
marker (Uherova et al., 2003). Molecular studies have shown that both L&H 
cells and HRS cells might derive from GC cells but L&H cells are derived 
from more mature and selected GC B cells (Kuppers et al., 1998). Classical 
HL is further grouped into 4 subtypes namely: lymphocyte predominance, 
mixed cellularity, lymphocyte depleted and nodular sclerosing. Each of these 
subtypes has a distinct histological morphology and phenotype as summarized 
in Table 1. The rate of occurrence and prognosis vary between each subtype 
(Mani and Jaffe, 2009; Townsend and Linch, 2012). 
 
As compared to reactive lymph nodes, HL have increased number of T cells 
(~70%) in their microenvironment. Notably most of the T cells are CD4+ T 
cells, but not CD8+ T cells which posses cytotoxic activity (Gorczyca et al., 
2002). This might be one of the factors which lead to the immune evasion of 
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HRS cells. Besides T cells, the HL microenvironment mainly consists of 
macrophages, B cells and eosinophils. 
 
Table 1. Characteristic of Hodgkin lymphoma subtype (Schmitz et al., 
2009) 
 
Lymphocyte predominance Nodular growth with large number of non-malignant 
infiltrating B cells 
 
Lymphocyte depleted High amount of HRS cells with little lymphocytes 
and histiocytes 
 
Mixed cellularity Infiltrating of lymphocytes, histiocytes, eosinophils 
and neutrophils without sclerosis 
 
Nodular sclerosis The most common subtype.  
Similar with mixed cellularity subtype but with 
collagen bands surrounding tumor nodular cluster 
 
 
In 1994, Kuppers et al. showed that HRS cells are originated from GC B cells 
after discovering the rearrangement of variable region of immunoglobulin 
genes in HRS cells. This finding suggests that the precursors of HRS cells are 
derived from GC B cells which have undergone somatic hypermutation 
(SHM). During SHM, activation-induced deaminase (AID) expression in GC 
B cell is upregulated and this initiates a very active single nucleotide 
substitution on variable region of immunoglobulin sequence in order to 
generate antibodies which will be more effective and specific against the 
foreign antigen (Teng and Papavasiliou, 2007). However, this process is 
highly randomized and error-prone. Thus as a protective mechanism, any GC 
B cell which has low antigenic affinity or with crippled B cell receptor (BCR) 
will be eliminated by apoptosis. 
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Further characterization of SHM on HRS cells revealed that at least part of the 
HRS cells have crippled BCR (Kuppers and Rajewsky, 1998). This means that 
the precursor of HRS cells that are supposed to be apoptotic in GC after SHM 
but somehow these precursor cells escaped the elimination pathway and 
transformed into HRS cells. The detailed etiology of HL and transformation of 
HRS cells is still unknown but the disease has been associated with Epstein–
Barr virus (EBV) infection. EBV infection was found in 30-50% of HL cases 
in developed countries, and escalated to nearly 50-100% in some other 
countries in Asia and Africa. The high association of EBV with HL suggests 
its potential involvement in the pathogenesis of HL. In addition to that, EBV 
infection might be negatively associated with a favorable prognosis of HL, 
although this finding is still controversial (Ambinder, 2007). 
 
EBV only expresses a handful of viral proteins but has a strong association 
with Burkitt lymphoma and HL pathogenesis. It was shown that EBV 
infection can immortalize GC B cells which do not have functional BCR 
molecules (Bechtel et al., 2005). This observation may explain how HRS cells 
manage to evade apoptosis in GC after they acquire crippled BCR sequences 
during SHM. Studies have also shown that EBV viral proteins can substitute 
some of the missing but essential survival signalling in HRS cells after SHM. 
Latent Membrane Protein 1 (LMP1) and LMP2 are among the most well 
characterized viral protein. LMP1 has been shown to induce a similar 
signalling pathway and function as compared to CD40, an important B cell co-
stimulatory molecule. LMP1 is also constitutively activated in infected cells 
(Lam and Sugden, 2003; Rastelli et al., 2008). On the other hand, LMP2 has 
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been shown to mimic BCR function and signalling while at the same time 
inhibiting normal antigen presentation function of BCR (Dykstra et al., 2001). 
Since BCR and CD40 signalling are the most important signals required for B 
cell activation, one would expect that EBV infected B cells become self 
sustaining in survival signalling and increase proliferation which are two of 
the hallmarks for cancer. Surprisingly, LMP1 or LMP2 overexpression in B 
cells has been shown to downregulate B cell related markers like BCR and 
CD20 on B cells and at the same time upregulate transcription of the genes 
which are related to the HRS cells phenotype (Portis et al., 2003; Vockerodt et 
al., 2008). These results have undoubtedly supported the involvement of EBV 
infected GC B cells in HRS cell emergence. 
 
1.1.2 Immunosuppressive microenvironment 
Like many other solid malignancies, HL is infiltrated with tumor infiltrating 
lymphocytes (TIL) which are unable to eradicate established tumors in vivo. It 
is suggested that this immunosuppressive nature of tumor microenvironment is 
due to predominance of a T helper 2 (Th2) and Regulatory T (Treg) cell 
response, which will be discussed below. 
 
TIL which are found in HL lesions are predominantly CD4+ CD25+ Treg cells 
with high expression of IL-10 and Cytotoxic T-Lymphocyte Antigen 4 
(CTLA-4). The TIL is also found to have a lower proliferation capacity and a 
reduced Interferon-gamma (IFN-γ) release (Koenecke et al., 2008; Marshall et 
al., 2004). Both of these are very important measurements for the anti-tumor 
activity of T cells. This is because the release of IFN-γ modulates T helper 1 
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(Th1) or cell-mediated responses and that the proliferation is required for the 
expansion of antigen specific T cells. Downregulation of these T cell 
responses might reduce T cell cytotoxicity, and might be the reason that leads 
to the immune evasion of HRS cells. Infiltration of Treg cells into HL might 
be partly due to the upregulation CCL17 and CCL22, important 
chemoattractants of CD4+ CD25+ Treg in HL patients (Niens et al., 2008). 
Interestingly, co-culturing of CD4+ T cells with a HRS cell line alone was 
shown to be able to induce Foxp3+ Treg cell differentiation (Tanijiri et al., 
2007). This suggests that at least some of Treg cells might be induced in the 
tumor microenvironment due to the influences of HRS cells.  
 
Besides that, HRS cells were also shown to preferentially secrete Th2 
cytokines and chemokines, especially Interleukin-6 (IL-6), IL-13 and IL-21 
(Lamprecht et al., 2008; Skinnider and Mak, 2002). The bias toward a Th2 
response in tumor microenvironment is commonly regarded as a survival 
advantage for cancer cells, as it suppresses Th1 responses and proper cell-
mediated immunity which are required for tumor rejection. Besides that, IL-13 
and IL-21 were also shown to be important autocrine growth factors for HRS 
cells (Kapp et al., 1999). However, c-Maf+ Th2 phenotypic cells in TIL have 
been shown to be associated with improved prognosis of HL patients. 
(Schreck et al., 2009). The reason of this contradictory observation has yet to 
be elucidated but suggests that it may be the ratio and functional balance 
between Th1 and Th2 cells in the HL microenvironment that is more 
important than their abundance in the pathogenesis of the tumor. 
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It is interesting to learn that EBV infection plays a role in the 
immunosuppressive environment in HL. Apart from inducing a HRS 
phenotype, LMP1 can also induce IL-10 secretion from CD4+ T cells, and 
subsequently suppress T cell proliferation and IFN-γ release (Marshall et al., 
2003). Besides that, LMP1 was shown to increase the promoter activity of 
Programmed cell Death 1 Ligand 1 (PD-L1) and lead to the upregulation of 
PD-L1 in HL (Green et al., 2012). PD-L1 will then interact with Programmed 
cell Death 1 (PD-1) which is expressed by T cells in HL and reduce IFN-γ 
release from T cells (Yamamoto et al., 2008). These are all potential 
mechanisms by which EBV can manipulate the microenvironment in HL, 
reduce Th1 responses and lead to a less cytotoxic environment. This 
immunosuppressive mechanism has been developed evolutionarily by virus to 
prevent cell mediated immunity against EBV-infected cells. However, EBV 
infection also protects HRS cells from an anti-tumor response and potentially 
assists in their survival. Moreover, EBV infected tumor cells were shown to 
upregulate CCL-17 and CCL-22 secretion which will cause the infiltration of 
Treg cells (Takegawa et al., 2008) and further impair host's immune responses. 
 
1.1.3 Association of HL with members of tumor necrosis factor receptor 
family  
Tumor necrosis factor receptor (TNFR) family members have been intensively 
studied in the context of HL (Skinnider and Mak, 2002). Among them, CD30 
is expressed by most of the HRS cells and is one of the most studied 
diagnostic markers for HL. The function of CD30 on HL cells has not been 
elucidated at the current stage, and there is speculation that CD30 signaling 
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might not be effective in HRS cells (Hirsch et al., 2008). Nonetheless, plenty 
of individual reports have shown CD30 signaling in HRS cells. Notably, it was 
shown that CD30 can increase Nuclear Factor Kappa B (NF-κB) and cellular 
FLICE inhibitory protein (cFLIP) activation in HRS cells (Boll et al., 2005) 
which will enhance HRS cell proliferation and protect them from Fas-
mediated cell death (Dutton et al., 2004; Mathas et al., 2004). Interestingly, 
proliferation of HRS cells decreases due to deactivation of NF-κB and 
Extracellular Signal-regulated Kinases (ERK) 1/2 pathway when CD30 is 
knocked down (Watanabe et al., 2011). In addition to that, CD30 can also 
inhibit T cell proliferation in co-culture experiments (Su et al., 2004). Due to 
high CD30 and HL association, different attempts were made to utilize CD30 
as a potential therapeutic target to specifically kill CD30+ cells (Dietlein et al., 
2010; Gualberto, 2012). 
 
Besides CD30, other TNFR family members like CD40, CD95, Receptor 
activator of NF-κB (RANK), Transmembrane Activator and Calcium 
modulator and cyclophilin ligand Interactor (TACI), and B Cell Maturation 
Antigen (BCMA) are also shown to be expressed by HRS cells (Chiu et al., 
2007; Fiumara et al., 2001; Kim et al., 2003). The finding of CD95 expression 
on HRS cells is very interesting, as CD95 is capable of inducing cell death by 
CD95-mediated apoptosis upon ligation with CD95 ligand (CD95L) (Wajant, 
2002). However, despite expressing high levels of CD95, HRS cells are 
resistant to CD95 mediated apoptosis (Metkar et al., 1999; Re et al., 2000). 
This resistance might be due to high cFLIP expression in HRS cells (Dutton et 
al., 2004; Mathas et al., 2004). Besides that, HRS cells also express high levels 
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of CD95L, but co-expression of CD95 and CD95L cannot cause apoptosis on 
HRS cells (Metkar et al., 1999; Verbeke et al., 2001). On the other hand, 
CD95L expressed by HRS cells might induce apoptosis of infiltrating T cells 
which express CD95 upon activation. 
 
CD40, TACI and BCMA expression on HRS cells were found to be functional 
and capable to increase proliferation of HRS cells upon stimulation (Carbone 
et al., 1995; Chiu et al., 2007). Besides that, CD40-CD40L interaction can 
induce rosette formation between T cells and HRS cells and cause an 
upregulation of Interferon regulatory factor 4 (IRF4) which might contribute 
to their pathogenesis (Aldinucci et al., 2010). Lastly, our group has shown that 
CD137 is expressed ectopically by HRS cells (Figure 1).  
 
Ectopic CD137 expression has a high correlation with HL with 86% of HL 
patients being positive for CD137 on HRS cells while CD137 expression was 
found to be absent in other subtypes of lymphoma as well as non-malignant 
reactive lymph nodes (Ho et al., 2012). Ectopic CD137 expression on HRS 
cells was also reported separately by another research group (Anderson et al., 
2012). Nonetheless, the function of CD137 and the mechanism of its 
upregulation in HRS cells have yet to be investigated. Interestingly, the EBV 
viral protein LMP1 was shown to upregulate the CD137 promoter activity in T 
cells and natural killer (NK) cells (Arai, 2009) but whether EBV causes the 
ectopic expression of CD137 in HRS cells has yet to be studied. 
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Therefore the main interest in this study is to investigate the effects of ectopic 
expression of CD137 on the survival of HRS cells. In the next section of 






Figure 1. CD137 expression on Hodgkin lymphoma  
Immunohistochemistry staining of paraffin-embedded Hodgkin lymphoma 
tissue for CD137 expression. High level of CD137 is expressed in cytoplasmic, 
Golgi and membrane area of HRS cells. A (400x), B (750x) and C. Isotype 









1.2 CD137 and CD137L  
1.2.1 Expression and characteristic of CD137 and CD137L  
CD137 is a member of TNFR superfamily and is also known as Induced by 
Lymphocyte Activation (ILA) or 4-1BB (Kwon and Weissman, 1989; 
Schwarz et al., 1993). CD137 is mainly expressed by T cells, dendritic cells 
(DC) and NK cells, and its expression is strictly activation-dependent under 
normal physiological conditions (DeBenedette et al., 1995; Schwarz et al., 
1995). CD137 Ligand (CD137L), the only known binding partner of CD137, 
is a member of Tumor Necrosis Factor (TNF) superfamily and also known as 
4-1BB ligand (4-1BBL) (Goodwin et al., 1993; Rabu et al., 2005). CD137L is 
expressed mainly by antigen presenting cells (APC) especially on monocyte, 
B cells and hematopoietic progenitor cells (Jiang et al., 2008b; Zhou et al., 
1995).  
 
Binding of CD137 to CD137L induces a bidirectional signalling whereby the 
signals will be conveyed downstream of CD137 and CD137L simultaneously 
into the cells they are expressed on (Figure 2). The combination of CD137-
CD137L signalling has been shown to be involved in the activation, 
maturation and differentiation of various immune cells and hematopoietic 
progenitor cells (Jiang et al., 2008a; Schwarz et al., 1996; Thum et al., 2009). 
 
CD137 and CD137L are involved in the modulation of immune responses. 
CD137 is expressed by T cells upon activation as a co-stimulatory molecule. 
Upon stimulation, CD137 can further enhance activation of T cells and their 
proliferation, induce IFN-γ release and also the cytolytic activity of T cells 
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(Cannons et al., 2001). Besides that, CD137 can reverse anergy and activation 
induced cell death (AICD) of T cells, and make restore their cytotoxicity in an 
immunosuppressive environment (Hernandez-Chacon et al., 2011; Wilcox et 
al., 2004). CD137L expressing tumor cells are shown to induce higher T cell 
cytotoxicity and Th1 responses, and CD137L knock out mice were shown to 
have increased chances to develop malignant growth (Li et al., 2008; 
Middendorp et al., 2009). All of these results have confirmed the roles of 
CD137 in stimulating Th1 and cytotoxic T cell responses, and also in 
enhancing cell-mediated immunity of T cells. Due to its therapeutic potential, 
CD137 has been studied extensively for its potential usage in tumor 
immunotherapy. The details will be discussed in next section. 
 
On the other hand, CD137L is constitutively expressed by APC and the 
reverse signaling via CD137L is best described in myeloid cells. CD137L 
stimulation induces activation and proliferation of monocytes (Langstein et al., 
1998; Langstein et al., 1999; Tang et al., 2011). Apart from that, CD137L 
stimulation can also induce human monocyte differentiation into DC. The 
CD137-differentiated DC are functional and have been shown to induce higher 
T cell responses than conventional DC which are generated by Granulocyte 
Macrophage Colony-Stimulating Factor (GM-CSF) + IL-4 (Kwajah and 
Schwarz, 2010). However, the outcome of CD137L stimulation on human and 
murine monocytes seems to be different. CD137L stimulation on murine 
monocytes fails to induce differentiation into inflammatory DC, and this 
suggests that there might be a species difference in CD137L signaling (Tang et 
al., 2011). 
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CD137L has been found to be expressed by B cells but the function of 
CD137L in B cells is poorly defined. Nonetheless, it is suggested that CD137L 
might be involved in the proliferation and also differentiation of B cells to 
antibody producing cells (Shao and Schwarz, 2011). 
 
Moreover, stimulation of CD137L is able to promote the differentiation of 
both human and murine hematopoietic progenitor cells into myeloid lineage 
cells, mainly monocytes and macrophages. CD137L stimulation was also 
shown to be able to suppress G-CSF-induced granulocytic cell differentiation 
of hematopoietic progenitor cells (Jiang et al., 2008a; Jiang et al., 2008b; Jiang 






















Figure 2. CD137 and CD137L bidirectional signaling 
CD137 is mainly expressed by activated T cells while CD137L is 
predominantly expressed by APC (e.g. B cells and monocytes). When CD137 
on T cells binds to CD137L on APC, co-stimulation will be induced which 
enhances T cell activation and proliferation. At the same time, a reverse 
signaling will also be initiated into APC which leads to the activation of APC 























1.2.2 Targeting CD137 for immunotherapy 
Due to the important function of CD137 in modulating immune responses, 
many researchers have tried to utilize CD137 as a means of immunotherapy. 
Among all the approaches, the usage of agonistic CD137 antibodies to 
enhance T cell anti-tumor activity has attracted much attention. For instance, 
the effects of agonistic CD137 antibody on tumor rejection have been studied 
extensively in vivo using several kinds of tumor model for example melanoma, 
liver cancer, lung cancer, myeloma and thymoma (Ju et al., 2005; Martinet et 
al., 2002; Murillo et al., 2008; Murillo et al., 2009; Zhu et al., 2009). Despite 
the differences in the models and methods used, they all showed that agonistic 
CD137 antibody effectively suppresses the tumor growth in vivo. Agonistic 
CD137 antibody is also currently in clinical trial to treat different kinds of 
cancer (Lynch, 2008; Wang et al., 2009). 
 
TIL are the lymphocytes that migrate into the tumor mass from the 
bloodstream. TIL play an important role in tumor rejection and high TIL count 
is usually associated with good prognosis (Eerola et al., 2000). Many 
independent groups have reported that the TIL count is increased after anti-
CD137 antibody treatment (Ju et al., 2005; Wilcox et al., 2002) and 
interestingly, the majority of the TIL was found to be CD4+ and CD8+ T cells 
(Ju et al., 2005; Martinet et al., 2002; Murillo et al., 2008; Wilcox et al., 2002). 
However, the effects of anti-CD137 antibody treatment on tumor regression 
were halted when CD8+ T cells were depleted or when the antigen presenting 
capacity of DC was affected. Anti-CD137 antibody treatment was also shown 
to induce the up-regulation of Natural-Killer Group 2, member D (NKG2D), 
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IL-2, IFN-γ and Tumor Necrosis Factor alpha (TNF-α) and the down-
regulation of IL-10, Transforming Growth Factor beta (TGF-β) and IL-4 
production (Zhu et al., 2009). This indicates that a Th1 immune response is 
triggered after anti-CD137 antibody treatment while the Th2 response is 
suppressed. 
 
On the other hand, secretion of IFN-γ was also found to be enhanced at the 
tumor site after anti-CD137 antibody treatment (Ju et al., 2005). IFN-γ was 
shown to increase the expression of Major histocompatibility complex (MHC) 
class I and class II in malignant cells (Ju et al., 2005; Murillo et al., 2008) 
which can lead to increased immunogenicity of tumor cells. This might be 
significant as TIL accumulation and a tumor suppression effect after anti-
CD137 antibody treatment cannot be observed in IFN-γ knock out mice (Ju et 
al., 2005; Murillo et al., 2008; Wilcox et al., 2002). This implies that IFN-γ is 
important in anti-CD137 antibody induced anti-tumor activity.  
 
Furthermore, immunomodulating effects of agonistic CD137 antibody could 
only be observed if anti-CD137 antibody treatment was given after the mice 
were inoculated with cancer cell (Ju et al., 2005). This suggests that the 
agonistic CD137 antibody might act on T cells that had been primed with 
tumor antigen but were unable to eliminate the tumor cells due to the lack of 





1.2.3 CD137 and CD137L in malignant diseases 
Despite being regulated strictly under normal circumstances, the expression of 
CD137 and CD137L has been found to be dysregulated in many disease 
models. Ectopic expression of CD137 was found in follicular DC tumor, T cell 
lymphoma, lung cancer and osteosarcoma (Anderson et al., 2012; Lisignoli et 
al., 1998; Zhang et al., 2007). As discussed earlier, CD137 is also ectopically 
expressed in 80-90% of HL cases. Constitutive expression of CD137 on these 
tumor cells is extraordinary as CD137 expression is activation-dependent 
under physiological condition. Besides that, CD137 expression was also found 
on the vessel wall of malignant tumors (Broll et al., 2001) which strengthens 
the correlation of ectopic CD137 expression with malignant growth. 
 
Soluble CD137 (sCD137), a product of differential splicing of CD137 
messenger RNA (mRNA), has been considered as an antagonist in nature, and 
acting as a competitor of membrane bound CD137 (Shao et al., 2008). CD137 
has been found to be upregulated in many autoimmune diseases, for example 
in systemic lupus erythematosus (SLE), pancreatitis and rheumatoid arthritis 
(RA) (Michel et al., 1998; Shao et al., 2008; Shao et al., 2012). In addition to 
autoimmune disease, serum levels of sCD137 were also found to be 
upregulated in many hematological malignancies, especially in non-Hodgkin 
lymphoma (Furtner et al., 2005). 
 
CD137L was found to be expressed by various cancer cells as well (Salih et al., 
2000; Wang et al., 2008). Surprisingly, these studies also showed that 
CD137L expressed by these cancer cells is functional and can induce IFN-γ 
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release from T cells upon ligation with CD137, indicating increases of anti-
tumor responses of T cells. Furthermore, CD137L expressed by multiple 
myeloma (MM) cells has been shown to induce apoptosis in MM cell lines 
upon stimulation (Gullo et al., 2010). The reason for these cancer cells 
expressing CD137L despite the potential disadvantage for tumor survival still 
remains unknown. One of the possibilities is that cancer cells might obtain 
some benefits from the downstream signaling of CD137L which has yet to be 
identified.  
 
Notably, CD137L is expressed by different subtypes of non-Hodgkin B cell 
lymphoma but absent in HL (Zhao et al., 2012). This coincides with the 
increase of serum sCD137 in non-Hodgkin lymphoma (NHL), which is found 
to be absent in HL (Furtner et al., 2005). In contrast, ectopic CD137 is only 
expressed by HL and rarely in NHL (Anderson et al., 2012). This complicated 
relationship of CD137, CD137L and sCD137 expression in HL and NHL 
might suggest that these proteins have an inter-dependent relationship in the 
pathogenesis of HL and NHL.  
 
1.3 Trogocytosis 
Trogocytosis is an intercellular transfer of membrane protein together with a 
fragment of plasma membrane (Davis, 2007). Its function is to facilitate the 
transfer of membrane protein between cells that have strong cell to cell 
interaction (as further discussed below). The exact mechanism for trogocytosis 
remains unclear so far. Nonetheless, it has been shown that the occurrence of 
trogocytosis is dependent on both cell types and on the surface protein 
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expression on the cells which are involved in the trogocytosis (Aucher et al., 
2008; Hudrisier et al., 2007). Cell to cell contact is also required for 
trogocytosis to occur (Beum et al., 2008; Gary et al., 2012; Pham et al., 2011).  
 
The force involved in the trogocytosis was shown to be equivalent to the force 
needed to break a strong protein-protein interaction (Bell, 1978). Thus, it is 
not surprising that trogocytosis is an active process that requires hydrolysis of 
ATP, activation of downstream signal (eg: src kinase) and remodeling of actin 
filament (Tabiasco et al., 2002).  
 
Transfer of cell surface material through trogocytosis was first described 
between DC and T cells, and the extent of this transfer is associated with DC-
T cells affinity and the T cell antigen specificity (Uzana et al., 2012). 
Immature DC which express fewer MHC and costimulatory molecules were 
found to be less active in trogocytosis compared to mature DC (Gary et al., 
2012). It has been shown that transfer of CD86 from DC to CTLA-4 
expressing Treg cells ceased when the CTLA-4 was neutralized (Qureshi et al., 
2011). In other words, this experiment suggests that the recipient cells must 
express the binding partner of the transferred material and the trogocytosis is 
ligand dependent. However, Gu et al. had opposed this theory by showing that 
CD80 and CD86 transfer from mature DC to Treg cells is independent of 
CD28 or CTLA-4 expression. Furthermore, transfer of OX40 ligand to OX40-
negative cells was also demonstrated (Baba et al., 2001), which again 
suggested that ligand specificity is not necessary for the transfer of materials 
between cells through trogocytosis. However, this ligand-independent transfer 
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of cell protein could be due to the transfer of bystander proteins which are in 
near proximity to trogocytosis site (He et al., 2007). 
 
The specific function of the trogocytosed protein is depended on the context of 
the transfer. However, most of the recent studies suggest that trogocytosis is 
more likely to be a negative feedback or a regulatory function (Helft et al., 
2008; Qureshi et al., 2011). For example, PD-L1 transfer from APC to T cells 
was shown to initiate apoptosis of PD-1 positive T cells (Gary et al., 2012). In 
addition, MHC class I molecules which co-transfer with MHC class II 
molecules from APC to CD4+ T cells causes the CD4+ T cells to become 
targets of cytotoxic T lymphocytes (CTL) cytolytic activity (Cox et al., 2007). 
 
Interestingly, trogocytosis was also observed between cancerous cells and 
their surrounding cells. Transfer of Human Leucocytes Antigen G (HLA-G) 
from tumor cells to monocytes can inhibit PHA activated Peripheral Blood 
Mononuclear Cell (PBMC) proliferation (HoWangYin et al., 2010). Similarly, 
transfer of material via trogocytosis was shown to upregulate N-cadherin on 
breast cancer cell lines, and potentially to enhance its invasiveness (Lis et al., 
2010). These findings suggest that trogocytosis might play a role in 
pathogenesis of malignant diseases. Nonetheless, the study of trogocytosis and 






1.4 Research objectives 
Above we discussed that ectopic CD137 expression is frequent in HL. CD137 
which can enhance the anti-tumor effect of T cells is overexpressed by HRS 
cells, while HL has a Treg and Th2 predominant immunosuppressive 
microenvironment. Is it possible that ectopic CD137 expression on HRS cells 
competes with the CD137 expressed by T cells and hence reduces T cell anti-
tumor activity? Besides that, CD137L which is commonly expressed by B cell 
lymphoma was also found missing in HL. All this evidence may indicate that 
ectopic CD137 expression plays a role in the pathogenesis of HL, and most 
likely benefits HL. 
 
Hence, the main objective of this study is to investigate the correlation of 
CD137 expression with the improved survival of HRS cells in HL, and to 
further examined the mechanisms behind this improved survival. 
 
Specific objectives of the study are: 
1. To elucidate the effects of ectopic CD137 expression on HRS cells and 
whether it can enhance survival of HRS cells 
2. If CD137 is beneficial to HRS cells survival, the mechanism of this 
beneficial effect shall be determined 





The results obtained in this study might provide new insights into the immune 
escape mechanisms of HL and other malignant diseases, and suggest a new 
























CHAPTER 2 MATERIALS AND METHODS 
2.1 Cells and cell culture 
2.1.1 Cell lines 
HRS cell lines (HDLM-2, KM-H2, L-428, L-540, and L-1236) were obtained 
from DMSZ-German Collection of Microorganisms and Cell Cultures. CD137 
expression on KM-H2 cells was knocked down by Ms Tan Teng Ee, NUS, 
using shRNA plasmid and Nucleofector Technologies (Lonza). CD137 
knocked down KM-H2 cells were denominated as KM-H2-CD137- cells. In 
addition, KMS-11 cells were kindly donated by Dr Cheng, National University 
Health System (NUHS), Singapore.  
 
These cell lines were cultured in RPMI-1640 medium (Sigma Aldrich) 
supplemented with 10-20% of fetal bovine serum (FBS, Biowest) and 2 mM 
of L-glutamine (Gibco) and were passaged every 3 to 4 days. 
 
2.1.2 CD137 overexpressing cell lines 
CD137 overexpressing L-428 and L-1236 cells were generated using lentiviral 
transfection. The CD137-pLenti6/V5-D-TOPO vector (Invitrogen) was 
constructed by Moh Mei Chung, NUS, while lentiviral transduction of L-428 
and L-1236 cells was performed at the Phoenix laboratory of Gene and Cell 
therapy, NUS, with the help of Dr Gan Shu Uin. Selection of positive clones 
was done by culturing the transfected cells in complete medium supplemented 
with predetermined doses of Blasticidin (5 µg/ml for L-428 cells and 0.5 
µg/ml for L-1236 cells). After the transfection, CD137 expression on L-428 
and L-1236 cells was confirmed by flow cytometry. CD137 overexpressing L-
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428 and L-1236 cells were denominated as L-428-CD137 and L-1236-CD137, 
respectively. 
 
2.1.3 PBMC isolation 
Isolation of PBMC was done using density gradient centrifugation. In brief, 
human buffy coats of healthy donors were purchased from Blood Donation 
Center, National University Hospital (NUH), Singapore. The buffy coats were 
diluted with Phosphate Buffer Saline (PBS) and 2 mM EDTA before it was 
layered on top of Ficoll-Paque PLUS (GE Healthcare). Centrifugation for 30 
min at 400 g pelleted the RBC below the Ficoll-paque layer while plasma and 
PBMC, a white fluffy thin layer formed the upper layer of the Ficoll-pague as 
shown in the Figure 3. PBMC were then isolated carefully from the layer and 
any contamination of RBC in PBMC was removed by incubating PBMC in 
Red Blood Cell (RBC) lysis buffer for 5 min. PBMC were then washed with 
PBS and kept at room temperature for further use. 
 
PBMC were cultured in RPMI1640 medium supplemented with 10% FBS, 2 













Figure 3. PBMC isolation with density gradient centrifugation. 
A schematic diagram shows isolation of PBMC using density gradient 
centrifugation. A diluted buffy coat was gently layered on top of the Ficoll 
solution before centrifuged at 400 g for 30 min. After centrifugation, PBMC 
were found accumulated as a thin fluffy layer between plasma and Ficoll and 




2.1.4 T cells, B cells and Monocytes purification 
Different subsets of PBMC were purified using magnetic activated cell sorting 
(MACS) by Miltenyi Biotec. In general, microbead-conjugated antibodies 
(anti-CD3 for T cells, anti-CD20 for B cells, and anti-CD14 for monocytes 
isolation) were diluted in MACS buffer (PBS with 0.1%BSA and 2 mM 
ETDA) and incubated with PBMC for 15 min at 4oC. The microbeads labeled 
PBMC were then loaded into a magnetic column. Positively labeled cells will 
be retained in the column by magnetic force while other non-specific cell 












positively labeled monocytes or B cells were later flushed out from the column 
and ready to be utilized. 
 
2.1.5 Storage of cell lines and primary cells 
Both cell lines and primary cells were occasionally frozen down for later use. 
Cell lines were resuspended in RPMI with 20% Fetal Bovine Serum (FBS) 
and 10% Dimethyl Sulfoxide (DMSO) with minimum cell concentration of 4 
x 106 cells/ml. On the other hand, primary cells were resuspended in RPMI 
with 40% FBS and 10% DMSO with minimum cell concentration of 2 x 107 
cells/ml. DMSO was added dropwise to the cell suspension. The cell 
suspension was then transferred to CryoTube (Nunc) and into a freezing 
container (Nalgene). The freezing container was then stored in -80oC freezer 
overnight, before the cryovials were transferred into liquid nitrogen tank. 
 
2.2 Antibodies and reagents 
An anti-CD3 antibody, clone Okt3, was purified from hybridoma supernatant 
by our previous colleague and was stored in -80oC for further used. Anti-
CD137 antibody clone BBK-2 was purchased from Labvision while clone 
JG1.6a was purchase from Novus Biologicals. On the other hand, anti-
CD137L antibodies, clone 41B436, clone 5F4, and clone C65-485 were 
obtained from Adipogen, Biolegend and BD Pharmigen, respectively. Anti-




Phycoerythrin (PE) labeled anti-CD137 antibody (clone 4B4-1) was purchased 
from BD Pharmigen while PE labeled anti-CD137L antibody (clone 5F4) was 
obtained from Biolegend. Anti-CD11b-APC antibody and anti-CD20-APC 
antibody were obtained from eBioscience. Mouse IgG1 (clone MOPC-21) 
which was used as isotype control was bought from Sigma-Aldrich and PE-
conjugated mouse IgG1κ was obtained from eBioscience. PE and APC labeled 
donkey anti-mouse secondary antibodies were purchased from eBioscience 
while Goat anti-mouse AF488 and Goat anti-rabbit AF597 secondary 
antibodies were obtained from Invitrogen. Monodansylcadaverine (MDC) was 
purchased from Sigma Aldrich. CFSE dye and PKH-26 dye were purchased 
from Invitrogen and Sigma-Aldrich, respectively.  
 
2.3 Flow cytometry 
Different combination of antibodies and isotypes were employed throughout 
this study. Nonetheless, basic protocol of flow cytometry was the same 
regardless of the experiment. First, cells were harvested and washed once with 
Fluorescence-Activated Cell Sorting (FACS) staining buffer (PBS, 0.5% FBS 
and 0.02% sodium azide). Then the cells were stained with either 
unconjugated primary antibody or primary antibody conjugated with 
fluorochrome at 4oC for 15 min followed by washing with FACS staining 
buffer. Cells stained with unconjugated primary antibody were then stained 
with secondary antibody conjugated with fluorochrome at 4oC for 15 min. The 
cells were then washed once with FACS staining buffer. 
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After the staining, the cells were resuspended in 400 µl of staining buffer with 
1% Paraformaldehyde (PFA) as fixative. The stained cells were analyzed 
using CyAn ADP analytical counter (Beckman Coulter) or LSR Fortessa 
analyzer (BD Biosciences) depending on the combination of fluorochrome 
used. The data was acquired in flow cytometry standard 2.0 (FCS 2.0) format 
and analyzed with Summit analysis software (Dako). 
 
2.4 Enzyme linked immunosorbent assay (ELISA) 
ELISA for IFN-γ from R&D Systems was performed according to the 
manufacturer's protocols. In brief, the diluted (if necessary) samples were 
incubated for 2 h in wells pre-coated with capture antibody. This was then 
followed by incubation with detection antibody for 2 h, streptavidin-HRP for 
30 min and eventually TMB substrate (BD bioscience). The plate was washed 
3 times with washing buffer (PBS and 0.05% Tween-20) between each 
incubation step. The reaction was stopped with 2N H2SO4 before analyzed 
using BioRad 680 microplate reader. Every sample was analyzed in duplicate. 
 
2.5 Western Blot 
2.5.1 Protein purification 
Cell samples were pelleted down and washed with ice cold PBS. The cell 
pellets were then resuspended in RIPA buffer (50 mM Tris, 150 mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-X and 1 mM of PMSF), 
incubated on ice for 10 min with gentle agitation and vortexed twice at 
maximum setting during the incubation period. After the incubation, the cell 
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lysates were centrifuged at 16,000 rpm for 10 min and the supernatants were 
aspirated and stored at -80oC for further use. 
 
2.5.2 Electrophoresis and electroblotting  
Protein samples were first electrophoresed on an acrylamide gel (Appendix I) 
using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
a PVDF membrane using wet transfer method. The apparatus used for 
electrophoresis and electroblotting were obtained from Biorad. In brief, equal 
amount of protein samples from each condition were boiled at 99oC with 
Laemmli Buffer (63 mM Tris, 10% glycerol, 2% SDS, 0.0025% bromophenol 
blue, 1.25% of 2-mercaptoethanol) for 10 min. The denatured protein samples 
were then loaded and electrophoresed on a 12% acrylamide gel at 150 V for 
70 min. Precision Plus protein standard (Biorad) was used as molecular 
marker. PVDF membrane was pre-activated with ethanol (30 sec in absolute 
ethanol, 2 min in distilled water and 5 min with transfer buffer) before usage. 
After electrophoresis, protein samples were transferred from polyacrylamide 
gel to pre-activated PVDC membrane at 100 V, max. 400 mA, for 60 min . 
 
2.5.3 Antibody probing and visualization 
The PVDF membrane was blocked with blocking buffer (PBS, 5% skim milk, 
0.05% Tween20) for 1 h at room temperature and probed with primary 
antibody overnight at 4oC. The membrane was then probed with secondary 
antibody for 1 h at room temperature. Antibodies were diluted in blocking 
buffer. Washing step was performed between each incubation step with 
adequate amount of washing buffer (PBS, 0.05% Tween20) for at least 3 x 10 
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min. The membrane was then visualized using SuperSignal West Pico or 
SuperSignal West Pico substrate solution (Pierce) depending on the strength of 
the signal and exposed to CL-XPosure film (Pierce). 
 
2.6 Co-immunoprecipitation (Co-IP) 
CD137L and CD137 were co-immunoprecipitated by anti-CD137 antibody. In 
brief, cell samples were lysed under non-denaturing condition using non-
denaturing lysis buffer (PBS, 1% Triton-X, 1 mM PMSF) for 10 min on ice 
with gentle agitation and vortex twice throughout the incubation. Cell lysates 
were then collected by centrifugation for 10 min at 16,000 rpm at 4οC. Protein 
concentration in total cell lysate was determined using a Bradford protein 
assay (Biorad). For every 1 mg of protein sample, 50 µl of protein-G coated 
agarose beads (Pierce) and 2 µg of anti-CD137 antibody (clone BBK-2) were 
added and the mixture was incubated overnight at 4oC on a rotator. On day 2, 
agarose beads were harvested by centrifuge at 16,000 rpm for 10 min and 
washed 4 times with complete lysis buffer. Protein was eluted by boiling the 
agarose beads in Laemmli buffer for 10 min and the eluted samples were 
subjected to Western Blot technique as described above for detection of 
CD137L.  
 
2.7 Confocal microscopy 
Cell samples were harvested, washed with PBS and fixed with 1% PFA for 15 
min at 37oC. The samples were then permeabilized with 0.2% Triton-X for 10 
min at room temperature. The samples were blocked with 1% BSA for 1 h at 
room temperature. Primary antibody staining was done at 4οC overnight 
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followed by secondary staining which was performed at room temperature for 
1 h. The samples were thoroughly washed with PBS for at least 3 times in 
between each step. The samples were counterstained with DAPI for 15 min at 
37οC and mounted on poly-lysine slide with ProLong Gold antifade reagent 
(Invitrogen). The slides were air-sealed with nail-polish and images were 
acquired using Olympus Fluoview FV1000 TIRF with the help from Ms Lee 
Shu Ying, Confocal Microscopy Unit, NUHS.  
 
2.8 Endocytosis inhibition assay 
Endocytosis inhibitor, MDC, was reconstituted with DMSO to the stock 
concentration (60 mg/ml) and was stored at -20oC. Prior to treatment, the stock 
solution was diluted with DMSO to 100 times of the desired concentrations 
respectively and was added to cell samples at constant ratio of 1:100. This is 
to ensure that the addition of DMSO in each of the condition is constant so as 
to avoid the unspecific effect caused by DMSO. Cell viability assay was done 
to determine the toxic dose of MDC. DMSO alone was used as a negative 
control.  
 
2.9 Cell viability assay 
Cell viability was determined by 7-Aminoactinomycin (7AAD) staining. 
7AAD solution was purchased from eBioscience. In brief, the samples were 
washed thoroughly with PBS before the addition of 7AAD solution according 
to the ratio recommended by manufacturer and incubated for 15oC. The 
percentage of 7AAD positive cells was then analyzed using flow cytometry 
(CyAn ADP analyzer, Beckman Coulter). 
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2.10 Trogocytosis assay 
PKH-26 membrane dye (Sigma) was used to quantify the transfer of plasma 
membrane material between cells. In brief, donor cells (L-428 cells and L-
1236 cells) were stained with 2 mM of PKH-26 for 3 min and the reaction was 
stopped by the addition of FBS. The cells were then washed 5 times using 
complete medium prior to use. At the same time, recipient cells (kms-11 cells) 
were labeled with 3 mM of CFSE (Invitrogen) for 15 min at 37οC and the 
reaction was quenched by the addition of ice cold complete medium. The cells 
were then washed 3 times prior to use. Donor cells and recipient cells were 
then co-cultured at the ratio of 1:1 for 24 h and stained for CD137 and 
CD137L expression as described previously. Transfer of PKH-26-labelled 
membrane cells between donor and recipient cells was measured using flow 
cytometry as described in flow cytometry section. CFSE gating was used to 
differentiate between donor and recipient cells. 
 
2.11 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
2.11.1 RNA extraction 
RNA was extracted using RNeasy Mini Kit (Qiagen). In brief, cell samples 
were harvested, resuspended in RLT buffer, and passed through 27 G needle 5 
times in order to homogenize the cells. 70% ethanol was used to precipitate 
RNA and the cell lysates were transfered to RNeasy mini-columns thereby 
trapping RNA in the columns. The columns were rinsed with RW1 buffer and 
centrifuged at 13,200 rpm for 1 min. The columns were then rinsed with RPE 
buffer and centrifuged at 13,200rpm for 1 min. RNA was eluted from the 
 34 
columns using RNase-free water followed by centrifugation at 13,200 rpm for 
1 min. 
 
2.11.2 Reverse transcription 
Total cDNA was generated using RevertAid™ First Strand cDNA Synthesis 
Kit (Fermentas). 2 µg of total RNA and 0.5 µg of oligo dT primer were mixed 
with RNA free water to a total volume of 12 µl. The mixture was mixed gently 
and incubated at 65oC for 5 min and chilled on ice. The following reagents 
were then added in the order as shown in Table 1 to a total volume of 20 µl. 
The mixture was then mixed gently and incubated at 42oC for 60 minutes 
followed by 70oC for 5 min. The cDNA was stored at -20oC for later usage. 
 
 
Table 2. RT-PCR reaction mix 
RNA template 12 µl 
5x Reaction Buffer 4 µl 
RiboLock RNase inhibitor (20 U/µl) 1 µl 
10mM dNTP 2 µl 
RevertAid M-MuLV Reverse Transcritptase (200 U/µl) 1 µl 









2.11.3 Polymerase chain reaction (PCR) 
5 µl of cDNA template from each sample was used for a PCR reaction. cDNA 
template was mixed with freshly prepared PCR master mix (Table 2) and 
topped up with nuclease free water to 50 µl. The primers used for this PCR 
were purchase from 1st Base Custom Oligos (FBCO) and their sequences are 
shown in Table 3. PCR was performed using Eppendorf automated thermal 
cycler with the setting as specified in Table 4. Products of PCR were then 
electrophoresed on a 3% agarose gel. The gel was stained with GelGreen 
(Biotium) and visualized using Chemi-Smart 3000 Gel Doc Imaging System. 
 
Table 3. Standard PCR reaction mix 
 
Table 4. Primers set for CD137L and cyclophilin PCR 
cDNA template 5 µl 
Mastermix:  
      10x Taq buffer 5 µl 
      Forward primer, 25µM 1 µl 
      Reverse primer, 25µM 1 µl 
      dNTP, 10µM 1 µl 
      Taq DNA polymerase, 5U/µl 0.5 µl 
Nuclease free water Top up to 50 µl 
Primer Sequence Size (bp) 
CD137L forward 5’AGCTTTCGCCCGACGATCCC 
CD137L reverse 5’GCACTCAGGTGCAGCAAGCG 
400 
Cyclophilin forward 5’GTCCAGCATTTGCCATGGAC 
Cyclophilin reverse 5’GACAAGGTCCCAAAGACAGC 
200 
 36 
Table 5. PCR thermal cycling for CD137L amplification 
Initial denaturation 95oC 5 min 
Denaturation 95oC 30 sec 
Annealing  63oC 45 sec 
Extension 72oC 60 sec 
Repeating cycle  40 cycles 
Final extension 72oC 10 min 
 
 
2.12 Light microscopic examination 
Light microscope was used to examine any morphological changes that 
happened throughout the experiment. Microscopic images were captured using 
Zeiss Axiovert 40 inverted microscope attached with Canon digital camera. 
 
2.13 Antibody treatment 
2.13.1 CD137 and CD137L neutralization 
To test the effects of CD137 neutralization, KM-H2 cells were treated with 5 
µg/ml of anti-CD137 neutralization antibody (clone BBK-2) and incubated for 
24 h prior to downstream experiments. In some of the experiments, CD137L 
was also neutralized using 5 µg/ml of anti-CD137L antibody (clone 5F4, 
41B436 or C65-485). 
 
2.13.2 Agonistic CD137 stimulation 
To determine which anti-CD137 antibody can induce higher CD137 
stimulation, both clone BBK-2 and JG1.6a antibodies were coated on 24 well 
plate and PBMC suboptimally activated with 0.5 ng/ml of anti-CD3 were 
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subsequently seeded (clone Okt3). The supernatants were collected and tested 
for their IFN-γ using ELISA as describe previously in ELISA section. 
 
Coating of anti-CD137 antibodies was done by diluting the antibody to 5 
µg/ml with PBS. 250 µl of the diluted antibody was added into a 24 well plate. 
The plate was then refrigerated at 4oC overnight. This is to ensure that the 
coating is sufficient. Any excess antibody was washed out from the well with 
PBS. The coated well was then ready for PBMC or HRS cells seeding. 
 
2.14 Statistics 
Data were expressed as mean ± standard deviation (SD) and statistical analysis 

























CHAPTER 3 RESULTS 
Infiltration of non-cytotoxic T cells is one of the hallmarks of HL. These T 
cells, which primarily consist of Th2 and Treg cells, are unable to eradicate 
tumor cells in vivo (as discussed in the Introduction). Interestingly, CD137, 
one of the T cell activation markers, was found to be expressed ectopically by 
HRS cells. Under normal circumstance, CD137 is mainly expressed by NK 
cells and cytotoxic T cells in a strictly activation dependent manner. In HL, 
HRS cells introduce a huge amount of additional CD137 into the tumor 
microenvironment that might interfere with the normal CD137-CD137L 
response, which is otherwise tightly regulated. In particular, CD137 
overexpressed by HRS cells might interfere with T cell activity which will 
lead to HRS cell survival its microenvironment. 
 
A series of experiments have been designed to address this question. In the 
first part of this chapter, how CD137 interferes with T cell activity via 
suppression of CD137L expression on HRS cells was shown. Next, whether 
ectopic CD137 can cause a similar CD137L suppression on surrounding cells, 
especially monocytes will be presented. Finally, the underlying mechanisms 
which cause this immunosuppressive event will be discussed in details. 
 
3.1 Screening and generation of HRS cell lines 
HRS cells constitute only about 1% of the total tumor mass in HL, which 
makes it technically challenging to obtain and isolate them. Thus, the 
experiments in this study involve immortalized HRS cell lines. There are total 
of 5 HRS cell lines which are commercially available and widely used for in 
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vitro studies, namely KM-H2, HDLM-2, L-428, L-540 and L-1236. All HRS 
cell lines were screened for CD137 expression by flow cytometry. Only KM-
H2 and HDLM-2 were positive for CD137 (Figure 4). This is not consistent 
with the observation where the majority of primary HRS cells were positive 
for CD137. Since the majority of HRS cell lines were established from 
secondary metastasized lesions of patients and have adapted to in vitro 
condition where the immune escape mechanism is unnecessary, I suppose 
some HRS cells might have lost their CD137 expression during this process. 
 
To generate a negative control for CD137-expressing HRS cell lines, one of 
our lab members has attempted to knock down CD137 in KM-H2 and HDLM-
2 cells by transfecting an shRNA plasmid into these HRS cell line using 
Nucleofector technique (Lonza). CD137 expression on KM-H2 cells was 
successfully knocked down, and the KM-H2-CD137- cells have a similar 
phenotype and characteristic as the empty vector transfected KM-H2 cells 
(KM-H2-control). KM-H2-CD137- cells do not express CD137 as shown by 
flow cytometry (Figure 5). 
 
In addition, L-428, L-1236 and, L-540 cells were transfected with CD137 
using lentiviral transfection. 100% of the transfected cells express CD137 after 
transfection and selection (Figure 6). The untransfected L-428, L-1236 and, L-



















Figure 4. Expression of CD137 on Reed Sternberg cell lines 
Expression of CD137 on Reed Sternberg cell lines was determined by flow 
cytometry. 105 cells from each cell line were stained for CD137. Open 
histograms: isotype. Grey histograms: anti-CD137 antibody (clone 4B4-1). 
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Figure 5. CD137 silencing on KM-H2 cells  
CD137 on KM-H2 cells was knocked down by using shRNA, and the 
expression of CD137 was tested by using flow cytometry. 105 cells from each 
cell line were stained for CD137. Open histograms: isotype. Grey histograms: 
anti-CD137 antibody (clone 4B4-1). The percentages of positively stained 







Figure 6. CD137 expression on L428, L540 and L1236 cells after CD137 
transfection 
L428, L540 and L1236 cells were stably transfected with CD137 using a 
lentiviral vector. Expression of CD137 on these cells after the transfection was 
determined by flow cytometry 105 cells from each cell line was stained for 
CD137. Open histograms: isotype. Grey histograms: anti-CD137 (clone 4B4-


















3.2 Ectopically expressed CD137 reduces the T cell stimulatory capacity 
of HRS cells 
3.2.1 Co-culturing HRS cells with PBMC and T cells 
HRS cells are found in a microenvironment comprising infiltrating 
lymphocytes, plasma cells and histiocytes. Therefore, it is interesting to 
examine the effect of ectopic CD137 by co-culturing HRS cells with these 
immune cells. PBMC comprising lymphocytes and monocytes are an easy 
source of these immune cells. Prior to the co-culture, PBMC were 
suboptimally activated with 0.5 ng/ml of anti-CD3 antibody (clone: Okt3, in 
order to activate the T cells for co-stimulation studies), and co-cultured them 
with either isotype-treated or CD137 neutralizing antibody-treated KM-H2 
cells for 24 h. The supernatants were collected and tested for IFN-γ release, 
which is an indicator for T cell activation. An increase in IFN-γ release 
whenever CD137 was neutralized was observed, as compared to isotype-
treated KM-H2 cells (Figure 7).  
 
To confirm this observation, KM-H2-control and KM-H2-CD137- cells were 
treated with anti-CD137 neutralizing antibody, prior to co-culture with PBMC. 
Comparing this result with the previous result, there is an increased IFN-
γ release when KM-H2-CD137- cells or CD137 neutralized KM-H2-control 
cells were used (Figure 8). Interestingly, no significant increase in IFN-
γ release was observed when KM-H2-CD137- cells were treated with CD137 
neutralizing antibody, probably because most of their CD137 has been 
knocked down. The slight increase in the IFN-γ could be due to the 
neutralization of residual CD137 on  KM-H2-CD137- cells after the knocked 
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down. As IFN-γ is predominantly secreted by activated T cells, the HRS cells 
were also co-cultured with purified T cells, and obtained a similar result when 
PBMC were used (Figure 8). 
 
The induction of IFN-γ release could be due to a synergistic effect of both 
allogeneic responses and co-stimulatory activity, as the PBMC were co-
cultured with haplotype-mismatched HRS cells. This is consistent with the 
observation of much lesser IFN-γ release in the PBMC alone condition (~500 
pg/ml, Figure 30). 
 
Interestingly, IFN-γ release from the T cells alone condition was lower 
compared to the release from PBMC. This could be due to the lack of APC in 
T cells alone condition, as the presence of APC (which expresses co-
stimulatory molecules) might be important for the proper activation and co-
stimulation of the T cells. 
 
IFN-γ promotes Th1 responses, antigen presentation and cytolytic activity. It 
is also one of the most important markers for measuring T cells responses, 
especially cytotoxic T cells and T helper cells type I.  These results suggest 
























Figure 7. CD137 neutralization on KM-H2 cells induces higher IFN-γ 
release from PBMC 
KM-H2 cells were pre-treated with 5 µg/ml of isotype (clone MOPC-21) or 
CD137 neutralizing antibody (Clone BBK-2) for 24 h, before co-culturing 
them with PBMC suboptimally activated with 0.5 ng/ml of anti-CD3 (Clone 
Okt3). IFN-γ release was measured by ELISA 24 h after co-culture. These 
data are representative of 3 independent experiments. Depicted are means ± 





































Figure 8. Impaired CD137 expression on KM-H2 cells leads to higher 
IFN-γ release from PBMC and T cells 
5 x 105 cells/ml of KM-H2-control and KM-H2-CD137- cells were pre-treated 
with 5 µg/ml of isotype (clone MOPC-21) or CD137 neutralizing antibody 
(clone BBK-2) for 24 h, before co-culturing them with 106 PBMC/ml or T 
cells suboptimally activated with 0.5 ng/ml of anti-CD3 (Clone Okt3). IFN-γ 
release was by ELISA measured 24 h after co-culture. These data are 
representative of 3 independent experiments. Depicted are means ± standard 
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3.2.2 Ectopically expressed CD137 down-regulates CD137L expression on 
HRS cells 
CD137 expression on T cells is upregulated after their primary stimulation. 
CD137 can induce co-stimulation in T cells upon crosslinking with CD137L 
and augment T cell proliferation and cytotoxicity. As CD137L is 
constitutively expressed by APC, we hypothesized that it may be also 
expressed on HRS cells which originate predominantly from B cells. 
Therefore, the CD137L expression on HRS cells and the effects of ectopic 
CD137 on this expression were examined. Surprisingly, CD137L expression 
on HRS cells increased about 2-fold, when CD137 was neutralized by 
antibody (Figure 9) or was knocked down by siRNA (Figure 10). This implies 
that CD137 and CD137L expression may have an inverse relationship, where 
ectopic expression of CD137 can down-regulate CD137L expression on HRS 


























Figure 9. CD137 and CD137L expression in KM-H2 cells after CD137 
neutralization 
KM-H2 cells were treated with 0.5 µg/ml of isotype (clone MOPC-21) or 
CD137 neutralizing antibody (clone BBK-2). After 24 h, the cells were stained 
for CD137 (clone BBK-2) or CD137L (clone 5F4). The same clone of CD137 
antibody was used for neutralization and staining to avoid competition 
between two antibodies. Staining antibodies were added in excess to ensure 
that the staining was consistent and comparable between conditions. Open 
histograms: isotype. Grey histograms: anti-CD137 (clone BBK-2). These data 
are representative of 3 independent experiments. The percentages of positively 








Figure 10. CD137L is upregulated in KM-H2 cells after CD137 silencing 
CD137 in KM-H2 cells were knocked down by using siRNA, and the 
expression of CD137L was measured by using flow cytometry. 105 cells from 
each cell line were harvested and stained for CD137L. Open histograms: 
isotype. Grey histograms: anti-CD137L (clone 5F4). The percentages of 




















3.2.3 Induction of IFN-γ release is due to CD137L upregulation after 
CD137 silencing 
CD137L is primarily expressed by APC, and upon ligation with CD137 on T 
cells, it acts as a co-stimulator of T cell activation. Therefore, it is 
hypothesized that increase in IFN-γ release is indeed due to increase in 
CD137L expression on KM-H2 cells after CD137 knock down or 
neutralization. To test this hypothesis, CD137L expression on KM-H2-CD137- 
cells was neutralized with various clones of CD137L neutralizing antibodies, 
before co-culturing them with PBMCs or T cells. As expected, KM-H2-
CD137- cells induce higher IFN-γ release from both PBMC (Figure 11) and T 
cells (Figure 12) after co-culturing. Two out of three clones of CD137L 
neutralizing antibodies used in this experiment managed to abrogate the 
induction of IFN-γ release caused by the CD137 knock down. Although there 
was low CD137L expression on KM-H2-control cells, it might not be 
sufficient to induce a T cell response, and therefore neither of these CD137L 
neutralizing antibodies significantly reduced IFN-γ release when the KM-H2-
control cells were co-cultured with PBMC or T cells. Since the induction of 
IFN-γ release after CD137 neutralization and knock down could be abrogated 
using anti-CD137L neutralizing antibodies, it may be due to CD137L 





















Figure 11. CD137L neutralizing antibodies abrogate the induction of IFN-
γ release from PBMC during co-culture with KM-H2-CD137- cells. 
5 x 105 cells/ml of KM-H2-control and KM-H2-CD137- cells were co-cultured 
with 106 cells/ml of suboptimally activated PBMC and their CD137L was 
neutralized with one of three clones of CD137L neutralizing antibodies, or 
their isotype control (5µg/ml). Antibody 1 - clone 5F4, antibody 2 - clone 
41B436, antibody 3 - clone C65-485. Supernatants were harvested 24 h later 
and tested for IFN-γ concentration by ELISA. Depicted are means ± standard 

















Figure 12. CD137L neutralizing antibodies abrogate the induction of IFN-
γ release from T cells during co-culture with KM-H2-CD137- cells. 
5 x 105 cells/ml of KM-H2-control and KM-H2-CD137- cells were co-cultured 
with 106 cells/ml of suboptimally activated T cells and their CD137L was 
neutralized with one of three clones of CD137L neutralizing antibodies, or 
their isotype control (5µg/ml). Antibody 1 - clone 5F4, antibody 2 - clone 
41B436, antibody 3 - clone C65-485. Supernatants were harvested 24 h later 
and tested for IFN-γ concentration by ELISA. Depicted are means ± standard 













In this section, it has been shown that ectopic CD137 expression on HRS cells 
can reduce T cell co-stimulation by downregulating CD137L expression on 
HRS cells. However, in the microenvironment of Hodgkin Lymphoma, there 
might be cell types other than HRS cells which express CD137L. For instance, 
both monocytes and B cells which constitutively express CD137L under 
physiological condition are also found in Hodgkin Lymphoma infiltrating cells. 
Will ectopic CD137 cause a similar downregulation of CD137L on these cell 
types as well? This possibility will be explored in the next section. In addition, 
the mechanism which leads to the downregulation of CD137L upon ectopic 
















3.3 Mechanism of CD137L disappearance 
We have confirmed that ectopic CD137 leads to a downregulation of CD137L. 
This subsequently causes a reduction in the T cell response and potential 
immune evasion of HRS cells. But thus far, the results do not explain what 
leads to the disappearance of CD137L.  
 
In this section, the underlying mechanism which leads to CD137L 
downregulation in CD137 expressing HRS cells was investigated. A few 
possible mechanisms of CD137 downregulation are as follows: 
a) Ectopic CD137 may alter transcription or translation of CD137L, and 
reduce the de novo synthesis of CD137L. 
b) Ectopic CD137 may affect the turnover rate of CD137L, by increasing 
internalization and breakdown of CD137L. 
c) Ectopic CD137 blocks certain epitopes on CD137L, which neutralizes 
its function and prevents the antibody to bind. 
 
We decided to use KM-H2 cells as the model to study the mechanism of 
CD137L downregulation, mainly due to KM-H2 cells expressing CD137 








3.3.1 CD137 neutralization does not affect CD137L mRNA expression 
Firstly, whether ectopic CD137 expression affects transcription of CD137L 
was investigated. KM-H2 cells were treated with anti-CD137 neutralizing 
antibody and mRNA expression was quantified by using RT-PCR. As the 
increase in CD137L was observed after 24 h of CD137 neutralization by using 
flow cytometry, the same time point was used in this experiment. Interestingly, 
no changes in mRNA expression can be observed (Figure 13). This suggests 













Figure 13. CD137 neutralization does not affect mRNA expression level of 
CD137L in KM-H2 cells 
KM-H2 cells were treated with 5 µg/ml of CD137 neutralizing antibody (clone 
BBK-2) for 24 h, and total mRNA of the cells was isolated as described in 
Materials and Methods. (A) mRNA expression of CD137L was determined by 
RT-PCR. Cyclophilin was used as internal control. (B) mRNA expression of 
CD137L was quantified (Image J) and normalized with cyclophilin expression. 

































3.3.2 CD137L protein expression increases after CD137 neutralization 
The interesting finding that CD137 neutralization does not affect CD137L 
transcription level led us to think whether CD137L expression on HRS cells 
was upregulated after CD137 neutralization. Is it possible for ectopic CD137 
to bind on CD137L and hence masking/hindering its function and also its 
detection by flow cytometry? To address this question, KM-H2 cells were 
treated with CD137 neutralizing antibody as described in Materials and 
Methods section, and the cells were lysed 24 h later. Denaturing RIPA buffer 
was used in cell lysis to ensure that protein-protein interactions are broken, so 
any bonding or epitope occupation would not interfere with detection of 
CD137L by Western Blotting. Surprisingly, CD137 neutralization does 
upregulate total CD137L protein level in KM-H2 (Figure 14), which means 
there is in fact a true increase in CD137L protein levels.  
 
Time course experiments were also performed, with samples being collected 
and lysed 24 h, 48 h, and 72 h after CD137 neutralization. The time course 
experiments have confirmed the result in Figure 14 and showed that CD137 
neutralization upregulate CD137L level on KM-H2 cells at different time 
points (Figure 15). This result also shows that the effect of CD137 
neutralization on upregulating CD137L is long lasting (up to 72 h after the 
treatment). 
 
By observing upregulation of CD137L protein level and unchanged CD137L 
mRNA level, we are able to deduce that CD137 expression on HRS cells does 
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not alter transcriptional activity of CD137L but it plays a role in increasing 








Figure 14. Total CD137L protein in KM-H2 cells was upregulated after 
CD137 neutralization 
KM-H2 cells were treated with 0.5µg/ml of CD137 neutralizing antibody 
(clone BBK-2), or its isotype control. After 24 h, the cells were lysed under 
denaturing conditions using RIPA buffer. 20µg of protein from each condition 
were used in Western Blot analysis for CD137L detection. GAPDH was used 








Figure 15. Upregulation of CD137L protein in KM-H2 cells after CD137 
neutralization 
KM-H2 cells were treated with 0.5µg/ml of CD137 neutralizing antibody 
(clone BBK-2), or its isotype. The cells were harvested at different time points 
(24, 72, and 96 h) and were lysed under denaturing condition using RIPA 
buffer. 20ug of protein samples from each condition were used in Western 
Blot for CD137L detection. The samples were stored at -80oC prior to usage. 
GAPDH was used as loading control. 
 
 




α-CD137  Isotype 
24 h 72 h 96 h 
α-CD137  Isotype Isotype α-CD137  
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3.3.3 CD137-CD137L co-localization in HRS cells 
CD137L is the only known binding partner of CD137 (Herbert Schwarz, 
personal communication). So it would not be a surprise if ectopic CD137 on 
HRS cells could interact with CD137L which is expressed by HRS cells as 
well. However, how strong is this CD137-CD137L interaction in HRS cells? 
To answer this question, a co-immunoprecipitation on KM-H2 cell lysate was 
performed with anti-CD137 antibody, and a Western blot was performed to 
measure the amount of CD137L pulled down with CD137. As expected, 
CD137L co-localized strongly with CD137 (Figure 16). This implies that 
CD137 and CD137L are not only co-expressed on KM-H2 cells, but at the 
same time, there is a strong interaction between the two molecules. In previous 
experiments, it is shown that CD137 neutralization actually leads to an 
increase of CD137L expression on KM-H2 cells. Is it possible the strong 
CD137-CD137L interaction plays a role in downregulation of CD137L on 
HRS cells? 
 
KM-H2 cells were treated with either isotype or CD137 neutralizing antibody 
for 24 h. The cells were then lysed and the extracts are subjected to co-
immunoprecipitation as described in Materials and Methods section. 
Interestingly, after neutralization of CD137, the KM-H2 cells showed less 
CD137-CD137L interaction compared to the isotype treated control cells 
(Figure 17). The CD137 neutralization was shown to upregulate CD137 and 
CD137L expression on KM-H2 cells (Figure 9 and 10), therefore, the 
reduction of the CD137-CD137L complexes after CD137 neutralization is 
unlikely to be caused by reduced CD137L expression. Instead, it is more likely 
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that CD137 neutralization affects the potential CD137-CD137L interaction. 
Some co-immunoprecipitation of CD137 and CD137L was observed in 
CD137-neutralized mock-IP condition, which might be due to the binding of 





























Figure 16. CD137L co-immunoprecipitates with CD137 in KM-H2 cells. 
KM-H2 cells were lysed with 1% Triton-X and the lysate was 
immunoprecipitated with either isotype control antibody (Mock-IP) or anti-
CD137 antibody (clone BBK-2, Co-IP). Precipitates were subjected to 
CD137L Western blot analysis. Equal amounts of protein lysate (1 µg) were 











Figure 17. CD137 neutralization reduces CD137 and CD137L interaction 
in KM-H2 cells. 
KM-H2 cells were treated with 5 µg/ml of anti-CD137 neutralizing antibody 
(clone BBK-2) or its isotype control. After 24 h, the cells were lysed with 1% 
Triton-X and the lysate was immunoprecipitated with either isotype control 
antibody (Mock-IP) or anti-CD137 antibody (clone BBK-2, Co-IP). 
Precipitates were subjected to CD137L Western blot analysis. Heavy chain of 
antibody was used as loading control. The slight increase in the CD137L 
pulled down in Mock-IP condition of CD137-neutralized KM-H2 cells is 
likely due to the binding of neutralizing antibody to the CD137-CD137L 




There is a strong CD137 and CD137L interaction in HRS cells, which can be 
abrogated by using CD137 neutralizing antibody. This led us to the next 
question, where are CD137 and CD137L colocalized in HRS cells? Confocal 
microscopy was used to answer this question. As expected, a strong 
colocalization of CD137 and CD137L in KM-H2 cells was observed. Most of 
this colocalization was found in the cytoplasm of KM-H2 cells, while some of 
it was scattered on the cell membrane (Figure 18). The colocalization of 
CD137 and CD137L in KM-H2 cells looks similar to the clustering of CD40 
upon stimulation, where CD40 forms a cap-like morphology and gets 
eventually internalized (Chen et al., 2006). It is possible that CD137L and 

















Figure 18. Colocalization of CD137 and CD137L in KMH2 cells. 
KM-H2 cells were stained for CD137 (clone BBK-2) and CD137L (clone 
5F4). Localization of the proteins was visualized by confocal microscopy.      


















3.3.4 CD137 and CD137L are co-internalized via endocytosis 
It is reported that members of TNF and TNFR superfamily can be co-
internalized upon ligation. TNF-Related Apoptosis-Inducing Ligand (TRAIL) 
was shown to be endocytosed quickly with Death Receptor 4 (DR4) and DR5 
upon ligation and hence reduces the effect of TRAIL induced cytotoxicity in 
tumor cells (Zhang and Zhang, 2008; Zhang et al., 2009). Moreover, 
endocytosis of CD95 and TNF-R1 were also observed (Eramo et al., 2004; 
Kohlhaas et al., 2007). The outcome and downstream mechanisms involved 
were found to be complicated and dependent on the context of their 
stimulation.  
 
Accumulation of CD137 in cytoplasm of HRS cells was found in clinical 
samples, although the function of CD137 in the cytoplasm remained unknown 
(Anderson et al., 2012). Consistent with this observation, a strong CD137 and 
CD137L colocalization was observed in the cytoplasm of KM-H2 cells 
(Figure 18). The CD137-CD137L complex which was observed in the 
cytoplasm might be the result of CD137 and CD137L internalization from the 
plasma membrane after their ligation. By eliminating CD137L from the cell 
surface, HRS cells gain survival advantages by limiting T cell costimulation as 
described in earlier part of my result section. 
 
To confirm this hypothesis, endocytosis in KM-H2 cells was inhibited using 
MDC, an inhibitor of clathrin-mediated endocytosis. Clathrin-mediated 
endocytosis has been involved in internalization and recycling of many cell 
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surface receptors, including other member of TNFR superfamily, e.g. CD95, 
DR4 and DR5 (Austin et al., 2006; Kohlhaas et al., 2007; Lee et al., 2006). 
 
Since MDC is toxic at high concentration and its effect varies with different 
cell types, the lethal dose of MDC was first determined for KM-H2 cells. KM-
H2 cells were treated with different concentrations of MDC (12.5-200 µM) 
and their cell viability were determined by using 7-AAD staining. At doses 
higher than 100 µM, a dramatic reduction in cell viability can be observed 
after 24 h (Figure 19). Hence the maximum MDC dose for KM-H2 should not 
be more than 50 µM. 
 
KM-H2 cells were treated with 50 µM of MDC for 24 h to inhibit their 
endocytosis. As shown in Figure 20, both CD137 and CD137L on KM-H2 
cells were upregulated after the 24 h of endocytosis inhibition. This suggests 
that under normal circumstance, CD137 and CD137L were internalized 
together via endocytosis, and MDC inhibits endocytosis and thereby restores 
the CD137 and CD137L expression partially. Interestingly, whenever 
endocytosis was inhibited simultaneously with CD137 neutralization, further 
increases in CD137 and CD137L expression were not observed. This implies 
CD137 neutralization and endocytosis inhibition might be redundant of each 
other. From there, it can be deduced that anti-CD137 antibody can bind to 
CD137, inhibit its interaction with CD137L, and hence reducing co-
internalization of the CD137-CD137L complex. Nonetheless, MDC treated 
KM-H2 cells have lesser upregulation of CD137 and CD137L as compared to 
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CD137 neutralized KM-H2 cells. That is likely due to the toxic nature of 







Figure 19. Toxicity titration of MDC on KM-H2 cells  
KM-H2 cells were treated with various concentrations of MDC as shown. 
After 24 h of treatment, the cells were harvested and stained with 7-AAD to 
determine their viability. 7-AAD+ populations were gated and the percentages 
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Figure 20. Inhibition of endocytosis increases CD137 and CD137L 
expression on KM-H2 cells 
KM-H2 cells were treated with 5 µg/ml of anti-CD137 neutralizing antibody, 
or its isotype control as described in Methods section. The cells were also 
treated with 50 µg/ml MDC or DMSO, respectively. The cells were harvested 
and stained for CD137 (A) or CD137L (B) 24 h later. Isotype staining is 
shown as open histograms and CD137 and CD137L staining are shown as 
grey histograms. The percentages indicate the positively stained populations. 








































3.3.5 Trogocytosis mediates CD137 transfer which causes CD137L 
downregulation 
Ectopic CD137 expression on HRS cells causes a reduction in T cell activation 
by increasing internalization of CD137L through endocytosis. Nonetheless, 
whether CD137 on HRS cells interacts with CD137L via cis (intracellular) or 
trans (intercellular) interaction remains unknown. It has been reported earlier 
that TNFR family members (e.g. OX40) can get transferred from a cell to the 
other through trogocytosis, which is a contact-dependent intercellular transfer 
of cell surface material accompanied by a transfer of plasma membrane 
fragments (Baba et al., 2001). This mechanism has been shown in various 
models to assist cells to cells acquisition of functional proteins or as a negative 
feedback mechanism to scavenge proteins which have been utilized. The 
extent of transfer through trogocytosis is often associated with a specific 
receptor-ligand interaction between cells involved in the trogocytosis (e.g. 
TCR - MHC class I or TCR - MHC class II induced trogocytosis, as discussed 
in Introduction).  
 
A strong interaction between CD137 and CD137L in HRS cells has been 
shown using co-immunoprecipitation (Figure 16). Hence, it is interesting to 
investigate whether this strong interaction can lead to the transfer of CD137 
between HRS cells, and more importantly, cause a reduction of CD137L. 
 
Donor cells, L-428 and L-1236 cells, were labelled with PKH-26, which is a 
lipophilic dye commonly used to monitor the transfer of plasma membrane 
fragments. The donor cells were then co-cultured with KMS-11 cells 
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overexpressing CD137L, which were used as recipient cells. The transfer of 
CD137 from donor to recipient cells, and also the extent of trogocytosis were 
measured 24 h later. This co-culture experimental set up is needed primarily 
because it will be difficult to measure transfer of CD137 and trogocytosis by 
using one single cell line (e.g. using KM-H2 cells alone), as any transfer and 
trogocytosis will be bi-directional between cells, and any effect of transfer will 
be cancelled off each other.  
 
After the co-culture, KMS-11 cells were found to be positively stained for 
PKH-26 in all co-culturing conditions, regardless of CD137 or CD137L 
expression on L-428, L-1236 and KMS-11 cells respectively (Figure 21). This 
PKH-26 transfer is most likely due to background trogocytosis between these 
cells, induced by some other strong protein-protein interactions ongoing 
between these cells. The residual and unbound PKH-26 dye on the donor cells 
which could contaminate the co-culture system might also lead to the increase 
of the PKH-26 background on KMS-11 cells. Interestingly, despite the high 
background of trogocytosis, a further increase in PKH-26 transfer was 
observed from both L-428-CD137 and L-1236-CD137 to KMS-11-CD137L 
cells, compared to KMS-11-control cells. This result implies that the level of 
trogocytosis is upregulated whenever CD137 and CD137L is present in 
between donor and recipient cells, and CD137 and CD137L interaction can 
increase cell-cell affinity, bringing two cells closer to each other, and allowing 
more trogocytosis to happen. This hypothesis is further strengthened when an 
increase in cell clumping was observed when L-428-CD137 or L-1236-CD137 
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cells were co-cultured with KMS-11-CD137L cells, as compared to other 




Figure 21. CD137 and CD137L induce trogocytosis between donor and 
recipient cells 
5 x 105 cells/ml of PKH-26 labeled L-428 (A) or L-1236 (B) cells were co-
cultured with 5 x 105 cells/ml of CFSE labelled KMS-11 cells. 24 h later, the 
cells were harvested and analyzed with flow cytometry. The population shown 
was gated on CFSE-positive (KMS-11) cells. The percentages indicate the 
number of positively stained cells as compared to background signal. MFI 
(mean fluorescent index) for the respective sample were also shown. These 
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Figure 22. The presence of CD137 and CD137L induce L-428 and L-1236 
cell aggregation with KMS-11 cells  
5 x 105 cells/ml of L-428 (A) or L-1236 (B) cells were co-cultured with 5 x 
105 cells/ml of KMS-11 cells. 24 h later, the images of cell clumping were 
captured under 100x magnification with an inverted microscope. Grayscale 











































To confirm whether CD137 transfers with trogocytosis, a similar experiment 
was performed and the cells were stained for CD137 and CD137L. As 
expected, an increase in CD137 transfer from L-428-CD137 (Figure 23A) and 
L-1236-CD137 cells (Figure 24A) to KMS-11-CD137L cells was observed. 
The transfer of CD137 is CD137L dependent since there can be no CD137 
transfer observed when KMS-11-control cells were used. Moreover, this also 
confirmed that CD137 transfer from donor to recipient cells is instead through 
trogocytosis. What is more exciting is that CD137L expression on KMS-11-
CD137L cells was downregulated following the CD137 transfer (Figure 23B 
and 24B). The downregulation of CD137L is also CD137 dependent, as no 
CD137L downregulation can be observed when KMS-11-CD137L cells were 
co-cultured with CD137 negative L-428 or L-1236 cells. The result also 
implies that the trans (intercellular) interaction between CD137 and CD137L 
plays a role in the CD137L downregulation induced by ectopically expressed 
CD137 on HRS cells. Nonetheless, this result does not rule out the possibility 
that a cis interaction is also involved in the CD137-CD137L ligation and 
CD137L downregulation, which will need to be further investigated. 
 
Surprisingly, a strong transfer of CD137L was also observed from KMS-11-
CD137L cells to L-428-CD137 cells (Figure 25) and L-1236-CD137 (Figure 
26) cells. The CD137L transfer is CD137 dependent, as no transfer can be 
observed from KMS-11-CD137L cells to L-428-control and L1236-control 
cells. This implies the transfer of CD137 and CD137L via trogocytosis might 
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be a bi-directional process, where both cells involved in the trogocytosis can 
be donor and recipient cells at the same time. 
 
 
Figure 23. Downregulation of CD137L on KMS-11 cells following 
CD137L dependent transfer of CD137 from L-428 cells to KMS-11 cells 
5 x 105 cells/ml of PKH-26 labeled L-428 cells were co-cultured with 5 x 105 
cells/ml of CFSE labeled KMS-11 cells. 24 h later, the cells were harvested 
and stained for (A) CD137 (clone BBK-2) or (B) CD137L (clone 41B436). 
The cells were then analyzed with flow cytometry. The population shown was 
gated on CFSE-positive (KMS-11) cells. Indicated are the percentages of 
positively stained cells as compared to isotype staining. This experiment was 
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Figure 24. Downregulation of CD137L on KMS-11 cells following 
CD137L dependent transfer of CD137 from L-1236 cells to KMS-11 cells 
5 x 105 cells/ml of PKH-26 labeled L-1236 cells were co-cultured with 5 x 105 
cells/ml of CFSE labeled KMS-11 cells. 24 h later, the cells were harvested 
and stained for (A) CD137 (clone BBK-2) or (B) CD137L (clone 41B436). 
The cells were then analyzed with flow cytometry. The population shown was 
gated on CFSE-positive (KMS-11) cells. Indicated are the percentages of 
positively stained cells as compared to isotype staining. This experiment was 
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Figure 25. CD137L transfer from KMS-11-CD137L cells to L-428-CD137 
cells 
5 x 105 cells/ml of PKH-26 labeled L-428 cells were co-cultured with 5 x 105 
cells/ml of CFSE labeled KMS-11 cells. 24 h later, the cells were harvested 
and stained for (A) CD137 (clone BBK-2) or (B) CD137L (clone 41B436). 
The cells were then analyzed with flow cytometry. The population shown was 
gated on CFSE- negative (L-428) cells. Indicated are the percentages of 
positively stained cells as compared to isotype staining. This experiment was 






























Figure 26. CD137L transfer from KMS-11-CD137L cells to L-1236-
CD137 cells 
5 x 105 cells/ml of PKH-26 labeled L-1236 cells were co-cultured with 5 x 105 
cells/ml of CFSE labeled KMS-11 cells. 24 h later, the cells were harvested 
and stained for (A) CD137 (clone BBK-2) or (B) CD137L (clone 41B436). 
The cells were then analyzed with flow cytometry. The population shown was 
gated on CFSE- negative (L-1236) cells. Indicated are the percentages of 
positively stained cells as compared to isotype staining. This experiment was 
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In this section, the underlying mechanism of CD137L disappearance on HRS 
cells induced by ectopic CD137 expression was defined. To summarize: 
 
1. CD137 can downregulate total CD137L protein levels in HRS cells, 
but does not influence CD137L transcription. 
2. CD137 forms a strong interaction with CD137L, and co-localized in 
the cytoplasm of HRS cells. 
3. CD137 is internalized with CD137L by HRS cells, and the 
internalization can be inhibited by inhibitors of the clathrin-dependent 
internalization pathway. 
4. CD137 neutralization can abrogate interaction and internalization of 
CD137 and CD137L. 
5. CD137 can get transferred from one cell to another through 
trogocytosis. This process is CD137L dependent, and can also induce 
downregulation of CD137L on the recipient cells. 
 
With these results, it is now assured that CD137 ectopically expressed by HRS 
cells can bind to CD137L on the surface of other cells via trans interaction, 
and later become co-internalized into the cytoplasm. By downregulating 
CD137L, HRS cells reduce T cell costimulation, and hence gain survival 





3.4 Transfer of CD137 to surrounding monocytes and B cells 
HRS cells are surrounded by infiltrating inflammatory cells which were shown 
to be crucial for HRS cells survival. These infiltrating cells provide cytokines 
and growth factors which are constantly needed by HRS cells. Interestingly, 
APC and T cells which are part of these infiltrating cells fail to eliminate HRS 
cells effectively. It was shown that Treg dominating the HL microenvironment 
can undermine an effective cytotoxic T cells response (Re et al., 2005).  
 
B cells and monocytes are APC which were shown to express CD137L 
constitutively (Shao and Schwarz, 2011). As described in the previous section, 
CD137 can be transferred through trans interaction and causes the 
downregulation of CD137L in HRS cells. Hence, it will be interesting to find 
out if ectopic CD137 expression on HRS cells can also cause downregulation 
of CD137L in their surrounding APC. 
 
In this section, transfer of ectopic CD137 from HRS cells to monocytes and B 
cells and whether this CD137 transfer causes the downregulation of CD137L 
was assessed. It was also investigated whether the downregulation of CD137L 







3.4.1 Ectopically expressed CD137 induces CD137L downregulation in 
monocytes  
First of all, the transfer of CD137 from HRS cells to the surrounding 
monocytes or B cells which express CD137L was studied. KM-H2 and 
HDLM-2 cells were co-cultured with PBMC which were sub-optimally 
activated with 1 ng/ml of anti-CD3 (clone Okt3). PBMC contain 10% of 
monocytes and B cells, respectively, hence they are an easy source and 
suitable for this co-culture experiment. After 24 h of co-culture, the cells were 
harvested and stained for CD11b or CD20 for the gating of monocytes or B 
cells. The cells were also stained for their CD137 and CD137L expression to 
observe the transfer of CD137 and its effect on CD137L. 
 
Monocytes and B cells are negative for CD137 under physiological condition 
(although there is a study reporting that B cells can upregulate their CD137 
expression upon BCR stimulation (Zhang et al., 2010)). Therefore, any 
expression of CD137 on monocytes and B cells would most likely be due to 
the transfer from HRS cells.  
 
It is possible that doublet cell formation between monocytes or B cells and 
HRS cells might lead to an artifact of CD137+  monocytes or B cells. However, 
with proper suspension of the cell mixture during the staining step, the 
incident of the doublet cells should be minimal, and it is unlikely to 




As shown in Figure 27 and Figure 28, monocytes and B cells have low or no 
CD137 expression when they were not co-cultured with HRS cells. 
Surprisingly, CD137 was transferred from HDLM-2 cells to monocytes and 
also from both HDLM-2 cells and KM-H2 cells to B cells. KM-H2 cells do 
not transfer or transfer only little CD137 to monocytes and B cells in contrast 
to HDLM-2 cells (Figure 27 and Figure 28). The difference in the CD137 
transfer might be due to higher CD137 expression on HDLM-2 cells as 
compared to KM-H2 cells (Figure 4). This is supported by the observation that 
transfer of CD137 is both CD137 and CD137L dependent (Figure 23-24). 
Hence, lesser CD137 is expected to get transferred from KM-H2 cells which 
have lower CD137 expression. Notably, one of my colleagues observed a 
much higher transfer of CD137 from CD137 overexpressing L1236 cells to 
both monocytes and B cells (Ho et al., 2012), which again confirms that the 
level of CD137 expression is positively associated with the CD137 transfer. 
 
In addition, the fluorescent background of monocytes was also increased when 
the monocytes were co-cultured with HRS cells. The exact cause of this 
enhanced fluorescent background on monocytes is unknown, but it might be 
associated with the morphology and granularity changes on monocytes when 




















Figure 27. Transfer of CD137 from HRS cell lines to monocytes 
5 x 105 cells/ml of KM-H2 or HDLM-2 cells were co-cultured with 106 of 
PBMC suboptimally activated with 1 ng/ml of anti-CD3 (Clone Okt3). 24 h 
later, the cells were harvested and stained for CD137 (clone BBK-2) and 
CD11b and analyzed using flow cytometry. The histograms shown are gated 
on CD11b+ population only. Open histograms show the isotype staining of 
CD137. The percentages of positively stained cells are shown in the 





















Figure 28. Transfer of CD137 from HRS cell lines to B cells 
5 x 105 cells/ml of KM-H2 or HDLM-2 cells were co-cultured with 106 of 
PBMC suboptimally activated with 1 ng/ml of anti-CD3 (Clone Okt3). 24 h 
later, the cells were harvested and stained for CD137 (clone BBK-2) and 
CD20 and analyzed using flow cytometry. The histograms shown are gated on 
CD20+ population only. Open histograms show the isotype staining of CD137. 
The percentages of positively stained cells are shown in the histograms. These 













Surprisingly, transfer of CD137 to monocytes or B cells does not induce a 
consistent downregulation of CD137L (as summarized in Table 5 and shown 
in Appendix IV). This observation is not tally with the data shown in Figure 
23 and Figure 24, where CD137 transfer always caused CD137L 
downregulation on KMS-11 cells. The reason might be that CD137L is hardly 
detected on primary cells when analysed using flow cytometry, hence any 
change in CD137L expression might be harder to be measured by using flow 
cytometry. 
 
To overcome this issue, Western blot instead of flow cytometry was used to 
observe CD137L downregulation after monocytes and B cells are co-cultured 
with HRS cell lines. The experiment was repeated by co-culturing L-428 cells 
with MACS-purified monocytes or B cells. After 24 h of co-culture, the 
monocytes and B cells were re-purified using MACS, and Western blot was 
done to determine CD137L protein levels in monocytes and B cells. 
 
In most of the experiments, the number of re-purified B cells was too low to 
run a Western blot, and only little or no CD137L could be detected on B cells 
using Western blots. The reason for this observation is unknown, but it might 
be due to the influence of HRS cells on the viability of B cells (Figure 29). 
Moreover, CD137L expression on L-428 cells was detected in this experiment, 
despite it was normally found to be negative or low expression with cell 
surface flow cytometry staining. Surprisingly, CD137L expressed by L-428 
cells has a higher molecular weight than the CD137L expressed by primary 
monocytes (25 kD). This finding suggests that L-428 cells might express a 
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different form of the CD137L which can not be translocated to cell surface 
and hence only be found in the intracellular compartment. However, the 
functions of this alternative form of CD137L is unknown, and this hypothesis 
needs to be further investigated. 
 
Are HRS cells expressing a different form of CD137L for their survival 
advantage? This question is not addressed here. But what is important is the 
difference in their molecular weight allows us to distinguish the CD137L 
originated from L-428 cells and the one originated from primary APC, since 
there is always a slight contamination of L-428 cells after the APC are re-
purified from the co-culture. 
 
From Figure 29, CD137L expressed by monocytes can be easily identified on 
the blot as bands which have the exact molecular weight of 25kD, while the 
bigger bands are from CD137L expressed by L-428 cells. Notably, CD137L 
on monocytes is downregulated whenever the cells are co-cultured with L-
428-CD137, but not L-428-control. This observation confirmed the hypothesis 
that CD137 transferred to monocytes causes the downregulation of CD137L 
on monocytes. Unfortunately, due to the low CD137L expression on B cells, 







Table 6. Changes in CD137L expression on monocytes and B cells after 






Figure 29. HRS cells induce CD137L downregulation on monocytes 
5 x 105 cells/ml of L-428 cells were co-cultured with 106 cells/ml of B cells or 
monocytes. 24 h after the co-culture, B cells and monocytes were re-purified 
from the co-culture by using magnetic column and then lysed using RIPA 
buffer. 40µg of protein samples from each condition were used in Western 
blot for CD137L detection. GAPDH was used as loading control. These data 
are representative of 3 independent experiments. 
 
 
 Co-culture with Monocytes B cells 
Experiment 1 HDLM-2 Decrease No change 
 KM-H2 Decrease No change 
Experiment 2 HDLM-2 Decrease No change 
 KM-H2 Decrease Increase 
Experiment 3 HDLM-2 No change No change 
    KM-H2    Increase Increase 
*Individual flow cytometry data is shown in Appendix IV 
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3.4.2 CD137 overexpressing cell lines abrogate IFN-γ release from PBMC 
HRS cells can transfer ectopic CD137 to both monocytes and B cells, and 
cause the downregulation of CD137L at least on monocytes, but what is the 
function of this mechanism? Will the CD137L downregulation on APC affect 
T cell activation? To confirm this, L-428 or L-1236 cells were co-cultured 
with PBMC for 24 h, and IFN-γ release was measured as an indicator of T cell 
activation. 
 
A significant decrease in IFN-γ release was observed when L-428-CD137 and 
L-1236-CD137 cells were co-cultured with PBMC, as compared to L-428-
control and L-1236-control cells (Figure 30). It was also shown in a parallel 
experiment that the T cells proliferation was reduced when they were co-
cultured with L-1236-CD137 cells (Ho et al., 2013). This reduction in IFN-γ 
release and proliferation is likely due to the downregulation of CD137L on 
monocytes, which subsequently causes the reduction in T cell activation. This 
observation is similar to the KM-H2 cells and PBMC co-culture experiment in 
Figure 7, but unlike KM-H2 cells, L-428 and L-1236 cells were stained 
negative for cell surface CD137L (Figure 25 and 26), hence any effect of 
CD137L downregulation will be due to the transfer of CD137 from HRS cells 
to their surrounding cells in the coculture. Nonetheless, we can not rule out the 
possibility of other mechanisms which could also be involved in the 
downregulation of IFN-γ as we observed (e.g. the HRS cells forming 
aggregates with monocytes and preventing them from interacting with T cells). 
Therefore, a more specific experiment like a monocyte-T cell co-culture is 
needed to further verify this hypothesis. 
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3.4.3 Summary 
Besides causing downregulation of CD137L on HRS cells, ectopically 
expressed CD137 also might get transferred from HRS cells to its surrounding 
APC, particularly monocytes. This causes the downregulation of CD137L on 
















Figure 30. CD137 expressing L-428 and L-1236 cells inhibit IFN-γ releases 
from PBMC 
5 x 105 cells/ml of L428 or L1236 cells were co-cultured with 106 cells/ml of 
PBMC suboptimally activated with 1 ng/ml of anti-CD3 (Clone Okt3). IFN-γ 
release was measured by ELISA 24 h after co-culture. Depicted are means ± 












3.5 Potential of CD137 and CD137L signaling on HRS cells 
Thus far, the potential beneficial effects of ectopic CD137 on HRS cells have 
been examined by testing its effect in the HRS cell microenvironment. HRS 
cells can reduce T cell activation by ectopically expressed CD137. 
Nonetheless, CD137 might have more functions. Many members of TNFR 
superfamily overexpressed by HRS cells have been shown to be beneficial to 
HRS cells by supporting downstream signaling. CD30 was shown to sustain 
constitutive activation of NF-κB in HRS cells (Boll et al., 2005). Another 
member of the TNFR superfamily, CD40, was shown to manipulate the 
cytokine response in HRS cells by upregulating IRF4 expression (Aldinucci et 
al., 2010). Hence, it will be interesting to look at whether stimulation of 
CD137 on HRS cells can induce a signaling in HRS cells, and subsequently 
mediate survival advantages. 
 
In this section, some preliminary experiments have been done to validate that 
CD137 on HRS cells is functional in initiating signal transduction will be 
presented.  
 
3.5.1 Agonistic anti-CD137 antibody 
Like other TNFR superfamily members, activation of CD137 involves the 
crosslinking of surface CD137. In order to crosslink CD137, the antibody 
needs to be bond to a solid surface. Therefore, anti-CD137 antibodies (clone 
BBK-2 or JG-1.6a) were coated onto a plate, and PBMC that had been 
suboptimally activated with 0.5 ng/ml of anti-CD3 were seeded (Clone Okt3). 
IFN-γ release was measured 24 h later. Activated T cells express CD137 on 
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their cell surface and upon ligation with the anti-CD137 antibodies coated on 
the well plate, will get costimulated and increase IFN-γ production. This can 
be used to determine which clone is optimal for CD137 stimulation. From 
Figure 31, we can deduce that clone JG1.6a can induce more IFN-γ release 
from PBMC than clone BBK-2, which indicates that JG1.6a induces a higher 
CD137 response. Hence, clone JG1.6a is more agonistic for CD137, and this 















Figure 31. Anti-CD137 antibody clone JG1.6a induces more IFN-γ release 
from PBMC than the anti-CD137 antibody clone BBK-2 
PBMC suboptimally activated with 0.5ng/ml of anti-CD3 (clone Okt3) were 
seeded in plates coated with 5µg/ml of anti-CD137 antibodies (clone BBK-2 
or JG1.6a) or their isotype. An untreated condition was included as a control. 
IFN-γ release was measured by ELISA 24 h after co-culture. Depicted are 





3.5.2 CD137 stimulation causes morphological changes in HRS cells 
To test whether CD137 stimulation can affect the physiology of HRS cells, L-
428-control or L-428-CD137 cells were seeded into plates pre-coated with 
anti-CD137 antibody clone JG1.6a for 48 h. After the incubation, a portion of 
the L-428-CD137 cells had become more adhesive to the plate and became 
elongated shape (Figure 32). However, no morphological changes can be 
observed on L-428-control cells and isotype treated L-428 cells, which 
confirm that the morphological changes were caused by CD137 signaling. 
Hence it is possible that agonistic anti-CD137 antibody does produce 
functional effect(s) on CD137 expressing L-428-CD137 cells and the ectopic 




















Figure 32. The CD137 agonistic antibody causes morphological changes 
on CD137 expressing L-428 cells 
L-428 cells were seeded in a plate coated with 5 µg/ml of anti-CD137 
antibody (clone JG1.6a) or its isotype control. The images were taken 48 h 
later using an inverted light microscope. Black arrows indicate the cells which 
become more adhesive and with elongated shape. 630x magnification. These 











3.5.3 Involvement of the cytoplasmic domain of CD137L in HRS cell 
signaling 
During optimization of the confocal microscopy experiment, an anti-CD137L 
antibody against the cytoplasmic domain of CD137L (cCD137L) has been 
used (clone: ERP1172Y). Interestingly, most of the signal produced by this 
antibody was localized in the nucleus of KM-H2 cells (Figure 33A). This is 
interesting as the staining of extracellular CD137L domain (clone 41B436) is 
solely found on the plasma membrane and in the cytoplasm (Figure 18). The 
reason why the extracellular domain and cytoplasmic domain of CD137L are 
found at different location in HRS cells is unknown, but that can be due to a 
proteolytic cleavage of CD137L. Nonetheless, the strong localization of the 
cCD137L in the nucleus suggests that a potential function of CD137L in 
regulating transcriptional activity. The localization of the cCD137L in the 
nucleus was also confirmed in a non-HRS cell line (Moh Mei Chung, personal 
communication). 
 
Proliferating KM-H2 cells can be easily indentified by looking at the DNA 
condensation via DAPI staining. Whenever KM-H2 cells were proliferating, 
the cells become negative for cytoplasmic CD137L staining (Figure 33B). 
This dramatic change and strong nucleus localization suggest that cytoplasmic 
CD137L might be a part of the transcriptional network of the HRS cells, and 














Figure 33. The CD137L cytoplasmic domain is present in the nucleus of 
non-proliferating KM-H2 cells 
KM-H2 cells were stained with anti-CD137 antibody (clone BBK-2) and anti-
cytoplasmic CD137L antibody (clone EPR1172Y) followed by appropriate 
secondary antibodies. The cells were counterstained with DAPI and visualized 
using confocal microscopy. Right panels were superimposed with DAPI 
staining to show the localization of the nucleus. A. Isotype staining. B. Non-
proliferating KM-H2 cells. C. White arrow shows the proliferating cells with 
chromosome condensation. Magnification 400x. These data are representative 














Ectopically expressed CD137 might support HRS cell survival in more 
complex ways than expected. Besides reducing T cell activation via 
downregulating CD137L, the CD137 also shows some potential of inducing 
signaling in HRS cells, which might enhance survival of HRS cells. That is 








































CHAPTER 4 DISCUSSION 
The functions of CD137 have been studied mostly on activated T cells and NK 
cells. Agonistic anti-CD137 antibodies are currently in clinical trials, and 
plenty of articles describe tumor rejection by anti-CD137 antibodies. CD137 
has also been reported to be expressed by other cell types like B cells and DC 
or during disease state like rheumatoid arthritis and osteosarcoma (as outlined 
in Introduction section). However, the number of studies on these autoimmune 
and malignant diseases is very limited and is often at an early stage. Thus, this 
study shows the tumor promoting effects of CD137 on HRS cells and the 
potential mechanism for this effect. This is also the first study documenting 
the transfer of CD137 to CD137L expressing cells, and a new mechanism of 
regulating CD137 and CD137L expression. 
 
4.1 Ectopically expressed CD137 abrogates T cell activity 
One of the emerging hallmarks of cancer is avoiding immune destruction. 
Many types of tumor cells were shown to be less immunogenic or capable to 
suppress the immune system via different mechanism in order to evade from 
the host's immune system (Hanahan and Weinberg, 2011). In HL, studies have 
found that HRS cells express high level of MHC class II, transporter-
associated proteins 1 (TAP-1) and TAP-2, while MHC class I was always 
positive in EBV+ HRS cells (Murray et al., 1998; Oudejans et al., 1996; Tzardi 
et al., 1996). These findings imply that HRS cells are indeed relatively 
immunogenic as compared to other cancer cells which have a compromised 
capability to antigen processing and presentation. Therefore, HRS cells must 
be using other mechanisms to escape from immune surveillance. 
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In this study, ectopic CD137 expression on HRS cell lines was confirmed, and 
hence in vitro experiments were possible to study the beneficial effect of 
ectopic CD137 expression in HL. As shown in Figure 7 and 8, when CD137-
silenced or CD137-neutralized KM-H2 cells were co-cultured with PBMC or 
T cells, an increase in IFN-γ release from PBMC and T cells was observed. 
This indicates an enhanced T cell activity. CD137-silenced and CD137-
neutralized KM-H2 were further characterized and it was revealed that 
ectopically expressed CD137 leads to the downregulation of CD137L (Figure 
9 and 10). CD137L is constitutively expressed by antigen presenting cells, 
therefore, it is not surprising that HRS cells which originate from GC B cells 
are also positive for CD137L. However, the expression of CD137L on 
malignant cells causes negative effects for their survival, as CD137L is a co-
stimulatory molecule for T cells responses. Indeed, the downregulation of 
CD137L on HRS cells was shown to play a role in the reduced T cell 
stimulation (Figure 11 and 12). All of these observations imply that ectopic 
CD137 expression on HRS cells can lead to the reduction of T cell activity.  
 
Upon encounter of antigen presented on MHC molecules, T cells undergo 
initial activation and co-stimulatory molecules like CD137 and CD28 are 
upregulated. Proper co-stimulation is always required for full T cell activation 
and prevents AICD and anergy in T cells. CD137 was shown to be a very 
potent co-stimulator in enhancing further T cell activation, proliferation, and 
in preventing T cells from becoming anergic (Cannons et al., 2001; 
Hernandez-Chacon et al., 2011). Hence, the downregulation of CD137L 
expression on HRS cells inevitably reduced their potential of inducing T cell 
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co-stimulation and T cell anti-tumor activity which constitutes a survival 
advantage to HRS cells. This may explain the reason why HRS cells are 
unable to stimulate proper T cell responses despite being immunogenic. 
 
The reduction of T cell activity induced by ectopic CD137 expression might 
be strongly related to the immunosuppressive environment observed in HL. 
Although infiltration of T cells into primary HL lesions is very common, most 
of the infiltrated T cells are either Th2 or Treg cells that show little capacity in 
anti-tumor responses (Koenecke et al., 2008; Marshall et al., 2004). Lack of 
the Th1 and CTL cells in HL microenvironment can be due to the absence of 
CD137L which leads to anergy and AICD of these cytotoxic populations. 
Interestingly, IFN-γ release from TIL is often downregulated in HL which is 
in line with the observation in this study (Marshall et al., 2004). 
 
Although other co-stimulatory molecules like CD80 and CD86 were shown to 
be expressed by HRS cells, their capability to induce anti-tumor T cell activity 
in HL was not investigated (Bolognesi et al., 2000; Murray et al., 1995; Vooijs 
et al., 1997). Therefore, it is uncertain if HRS cells can induce effective anti-
tumor responses via their CD80 and CD86 expression even when CD137L is 
downregulated. Nonetheless, stimulation of CD137 alone using either 
agonistic CD137 antibody (Ju et al., 2005; Martinet et al., 2002; Murillo et al., 
2008; Murillo et al., 2009; Zhu et al., 2009) or exogenous expression of 
CD137L in tumor cells (Li et al., 2008) have been shown to eradicate 
established tumors in immunocompetent hosts, indicating that CD137 
stimulation can enhance anti-tumor responses even in the presence of CD28 
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stimulation. CD137L knock-out mice were also shown to have a higher chance 
of developing GC B cell lymphoma throughout their life time (Middendorp et 
al., 2009). These findings again imply the involvement of CD137L and CD137 
in immune surveillance, and that the downregulation of CD137L plays a role 
in the pathogenesis of HL. 
 
In fact, CD137 inducing CD137L downregulation on HRS cells has already 
been suggested in vivo. Two consecutive studies done by Natkunam's group 
have shown that CD137 is highly expressed in the primary tumor of HL 
patients while CD137L expression is absent in all HL (Anderson et al., 2012; 
Zhao et al., 2012). This inverse relationship of CD137 and CD137L 
expression is consistent with our finding in vitro. Interestingly, despite the 
absence of CD137L expression in HL, some of the subgroups of NHL were 
found to have high expression of CD137L while they were tested negative for 
CD137 (Anderson et al., 2012; Zhao et al., 2012). This mutually exclusive 
relationship between CD137 and CD137L expression in primary tumors 
implies that CD137 inducing CD137L downregulation indeed occurs in in vivo. 
However, high expression of CD137L on NHL cells is a clear survival 
disadvantage for NHL tumors as it will enhance T cell co-stimulation. NHL 
cells might have developed other mechanisms in order to counteract the 
disadvantage caused by the CD137L expression. One of the possibilities is via 
sCD137 that is often upregulated in serum of NHL patients (Furtner et al., 
2005). sCD137 can act as a competitor of membrane bound CD137 and hence, 
neutralize the effect of CD137L and diminish anti-tumor immune responses. 
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Considering that HRS cells comprise as little as 1% of the total HL mass, the 
effect of CD137L downregulation on HRS cells alone might not be sufficient 
in orchestrating the whole immunosuppressive environment that is observed in 
HL. Thus, the effects of ectopically expressed CD137 on infiltrating cells in 
HL were also examined in this study. Surprisingly, transfer of CD137 from 
HRS cells to their surrounding cells and especially monocytes is possible as 
demonstrated in the co-culture experiment (Figures 27 and 28). The transfer of 
CD137 causes CD137L downregulation on the monocytes which subsequently 
leads to reduced IFN-γ release from T cells when co-cultures were performed 
(Figure 29 and 30). This finding confirms that the CD137L downregulating 
effect of CD137 is not only restricted to HRS cells but also causes a reduction 
of CD137L expression on monocytes in the HL microenvironment. This 
actually has a larger effect on establishing immunosuppressive conditions 
since the majority of the HL tumor mass is made up of APC like macrophages 
and B cells, and CD137L downregulation on these cells will produce a more 
substantial immunosuppressive effect than CD137L downregulation on HRS 
cells alone. 
 
It is worth noting that a higher ratio of HRS cells was used in the current in 
vitro study. However, the number of HRS cells in the primary HL lesion is 
much lower, hence the total incidents of a HRS cell coming in contact with 
another HRS cell or their surrounding APC will also be reduced. Therefore, it 
is likely that the ectopic CD137 expression on HRS cells might induce a lesser 
immunosuppressive effect in in vivo condition, as compared to the current 
models used in this study. As a result, it is proposed that HRS cells might need 
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to adopt other mechanisms to suppress the host immune response further. For 
example, the release of soluble factor which can neutralize great amounts of 
CD137L or CD137 in their vicinity, or the release of other immunosuppressive 
cytokines. 
 
Figure 34 is a schematic illustration on how HL escapes from immune 
surveillance by ectopic CD137 expression. Under normal circumstances, 
CD137- malignant B cells will be removed by the T cell anti-tumor activity 
which is induced by binding of CD137 on T cells to CD137L expressed by 
both malignant B cells and their surrounding APC. However, by expressing 
ectopic CD137, HRS cells can induce downregulation of CD137L on both 
HRS cells and APC (especially monocytes), and reduce T cell co-stimulation, 














Figure 34. Ectopic CD137 promotes HRS cells survival via 
downregulation of CD137L expression (Ho et al., 2012) 
Under normal physiology conditions (A), Malignant B cells and APC (B cells 
and monocytes) express CD137L on their cell surface, thereby co-stimulating 
T cells and enhancing T cell cytotoxicity that leads to the removal of tumor 
cells. By overexpressing CD137 (B), HRS cells can downregulate CD137L 
expression on both HRS cells and APC through internalization of the CD137-
CD137L complex, and gain survival advantages by reducing T cell co-







4.2 CD137 trogocytosis 
Intercellular transfer of membrane material emerged as an important topic 
recently, and the transfer was shown to be crucial in maintaining cell to cell 
communication and regulation of cellular function especially in the central 
nervous system and immune system. The most common mechanisms involved 
in the transfer of membrane material are nanotube formation, exosome 
secretion and trogocytosis. Among these mechanisms, trogocytosis actively 
regulates immune responses. However, the detail on how membrane material 
is transferred through trogocytosis is not fully understood thus far (Ahmed and 
Xiang, 2011; Rechavi et al., 2009). 
 
In this study, CD137 was found to be transferred from HRS cells to their 
surrounding cells, especially to monocytes or to another tumor cell line via 
trogocytosis. When CD137 binds to CD137L, the transfer of CD137 occurs 
via trogocytosis, followed by the internalization of the CD137-CD137L 
complex into the cytoplasm. Removal of CD137L from the cell surfaces 
reduces the amount of CD137L present in the HL microenvironment and leads 
to the reduction of T cell costimulation. 
 
Trogocytosis of CD137 was solely described in the context of HL in this study, 
and how this process enhances survival advantages of HRS cells in their 
microenvironment. However, it is unlikely that trogocytosis of CD137 is only 
participating in the pathogenesis of HL. Rather, CD137 trogocytosis and 
CD137L downregulation is hypothesized to be involved in the normal 
regulation of CD137-CD137L and in modulating immune responses, while 
 100 
HRS cells just adopt this mechanism for their benefit. By extrapolating the 
observations in this study, there is a good possibility that trogocytosis of 
CD137 serves as a negative feedback mechanism in order to remove CD137L 
from APC after sufficient T cell costimulation. However, this idea was not 
explored in this study, and further empirical evidence is needed to confirm this 
assumption. 
 
In fact, some unpublished data from our group suggest the possibility of an 
involvement of CD137 trogocytosis in other conditions besides HL. For 
example, transfer of murine CD137 had been shown from the CD137-
overexpressing A20 cell line (murine B cell lymphoma) to monocytes or other 
cancer cell lines through trogocytosis. The transfer of murine CD137 was also 
accompanied by the downregulation of CD137L expression in recipient cells. 
CD137 knock out mice also express more CD137L compared to wild type 
mice (personal communication, Herbert Schwarz). This inverse relationship of 
CD137 and CD137L expression in mice is comparable to the findings in HL, 
thus suggesting that CD137 might be involved in the turnover of CD137L in 
other systems. 
 
Notably, Treg cells were also shown to acquire CD80 and CD86 from APC 
via trogocytosis and this leads to the downregulation of CD80 and CD86 in 
these APC. (Gu et al., 2012; Qureshi et al., 2011). The downregulation of 
CD80 and CD86 on APC weakens the stimulation of T cells through CD28, 
and thus affects T cell activation. These findings are similar to the 
observations in HL in this study, where ectopic CD137 expression induces 
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CD137L downregulation on HRS cells and APC, and thus reduces T cell 
activity. Therefore, it is not surprising if CD137 trogocytosis is involved in the 
regulation of immune response as suggested. 
 
4.2.1 CD137 and CD137L transfer 
Rather than being a random event, CD137 transfer is a highly organized and 
CD137L-dependent process as shown in this study. The transfer of CD137 
was shown to occur from CD137 overexpressing HRS cells only to KMS-11-
CD137L cells but not to KMS-11-control cells. Both KMS-11-CD137L and 
KMS-11-control cells have a high background of trogocytosis (as shown by 
high PKH-26 transfer in Figure 23) but only KMS-11-CD137L cells can 
induce the CD137 transfer from HRS cells. This implies that the transfer of 
CD137 is dependent on CD137L expression on recipient cells regardless of 
other ongoing transfers of protein and membrane material between donor and 
recipient cells. The specificity in the CD137 transfer may ensure that the 
efficiency of the transfer is maximized by avoiding the transfer to non-specific 
cells. 
 
The specificity in the transfer of membrane proteins is not restricted to CD137 
but was also described in the transfer of CD80 and CD86 from APC to CTLA-
4 expressing T cells, and the transfer of Killer-cell Immunoglobulin-like 
Receptor (KIR) from NK cells to MHC class I expressing cell (Qureshi et al., 
2011; Vanherberghen et al., 2004). Unspecific intercellular transfer of 
membrane proteins was also reported (Baba et al., 2001; Gu et al., 2012), 
however it is likely that those unspecific transfers are transfers of bystander 
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proteins. He et al. showed that MHC class I molecules are co-transferred as 
bystander proteins with MHC class II molecules when they share the same 
lipid rafts. This implies that a protein might be transferred if it is present in a 
close proximity of a trogocytosis site even if there is no specific binding 
partner for it. But in the case of CD137, no CD137 was transferred non-
specifically from HRS cells to CD137- KMS-11 cells, which suggests that 
CD137 is not transferred as bystander protein at least in HRS cells. 
Nonetheless, unpublished data from our group show murine CD137 might be 
transferred in a CD137L independent manner in B cell lymphoma models, 
thus suggesting that the CD137L dependency of CD137 transfer might vary 
depending on the species or circumstances (Pang Wan Lu, personal 
communication). 
 
Besides CD137 transfer, it is surprising that CD137L also get transferred from 
CD137L-expressing cells to CD137-expressing HRS cells, and that the 
transfer of CD137L is also strictly CD137 dependent (Figure 25 and 26). Bi-
directional transfer of membrane protein is not restricted to CD137 and 
CD137L since bidirectional transfer of KIR and MHC class I molecules was 
also reported (Carlin et al., 2001; Vanherberghen et al., 2004). However, the 
reason for this bi-directional transfer of CD137 and CD137L between cells has 
not been investigated in this study. The hypothesis is that CD137L acquired by 
HRS cells might continue to induce CD137 signaling in HRS cells which will 
enhance their survival. Besides that, CD137L transfer might also cause the 
removal of CD137L from HRS cells and APC, and lead to reduced T cell co-
stimulation. 
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4.2.2 Aggregation of CD137 and CD137L in the cytoplasm 
Trogocytosis of CD137 is followed by the removal of CD137L from the cell 
membrane. Aggregation of the CD137-CD137L complex in the cytoplasm of 
HRS cells was also observed, and it is most likely an event following the 
CD137 trogocytosis, thereby removing the CD137-CD137L complex from the 
cell surface (Figure 18). Interestingly, the aggregation of CD137 was also 
shown by Anderson et al. in primary HRS cells in HL lesion. This is a strong 
verification of in vitro result in this study in in vivo condition. However, no 
indication of the reason for CD137 aggregation in HRS cells was provided in 
Anderson et al. study. 
 
Even though the co-internalization of the CD137-CD137L complex was not 
described in any system prior to this study, the internalization of other TNFR 
superfamily members has been shown extensively. For instance, CD40, CD95 
and TNF-R1 were shown to be internalized quickly upon ligation of their 
respective ligands (Chen et al., 2006; Eramo et al., 2004; Kohlhaas et al., 2007; 
Mosselmans et al., 1988; Reinehr and Haussinger, 2008). The internalization 
process was deemed to be critical for proper signaling of these TNFR 
members in most of the studies. Besides that, other TNFR family members, 
TACI and BCMA, were found to colocalize with their respective ligands, 
BAFF and APRIL, in the cytoplasm of HRS cells. The signals transduced by 
TACI and BCMA were shown to enhance HRS cells survival by upregulating 
anti-apoptotic regulatory proteins (Chiu et al., 2007).  
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As discussed, internalization and clustering of members of TNFR superfamily 
is essential for their downstream signaling and proper function, thus, there is a 
possibility that the aggregation of CD137 in the cytoplasm of HRS cells has 
similar properties. Stimulation of CD137 was shown to activate NF-κB 
pathway (Arch and Thompson, 1998; Jang et al., 1998), which is a survival 
advantage for HRS cells. Therefore, it is possible that the aggregation of 
CD137 in the cytoplasm leads to the continuous CD137 signaling in HRS cells 
and partly contributes to the constitutive upregulation of NF-κB in HRS cells. 
 
4.3 CD137 and CD137L induce signaling into HRS cells 
Besides promoting tumor cell survival through modulating immune responses 
in the HL microenvironment, CD137 was shown in this study to stimulate 
morphological changes in HRS cells (Figure 32), which suggests the potential 
of CD137 signaling into HRS cells. This result is still at a preliminary stage, 
and the outcome of the signaling through CD137 is still unknown thus far. 
However, it is likely that the signaling transduced by CD137 is favorable to 
HRS cell growth. 
 
HRS cells were shown to express many members of the TNFR superfamily on 
their cell surface, and the expression of these TNFR superfamily members is 
beneficial to HRS cells. Particularly, CD30, CD40 and TACI were shown to 
activate NF-κB in HRS cells upon stimulation (Annunziata et al., 2000; Boll et 
al., 2005; Chiu et al., 2007). NF-κB has been shown to be an important 
transcription factor contributing to the pathogenesis of HL, and blockage of 
NF-κB activity reduces proliferation of HRS cells (Younes et al., 2003). Apart 
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from that, CD137 was also shown to induce NF-κB activity (Arch and 
Thompson, 1998; Jang et al., 1998). Since CD137 signaling in HRS cells is 
functional, it is possible that constitutive expression of CD137 can be 
contributed to the constant activation of NF-κB found in HL. However, this 
hypothesis needs to be further tested. 
 
One of the most unexpected findings from this study is the presence of 
cCD137L in the nucleus of HRS cells while full length CD137L is primarily 
found in the cytoplasm and the cell membrane (Figure 18 and 33). This 
finding was confirmed in a non-HRS cell line by a colleague in my lab, hence 
ruling out the possibility of an artifact (Moh Mei Chung, personal 
communication). Whether cCD137L has a role in the pathogenesis of HRS is 
not elucidated in this study. However, based on its nuclear localization and 
disappearance during mitosis, it is speculated that cCD137L might be involved 
in the transcriptional activity of HRS cells. cCD137L may also participate in 
the signaling in non-malignant cells, rather than just in HL. Nevertheless, this 
hypothesis has yet to be investigated. 
 
cCD137L is not the only cytoplasmic domain of a membrane bound protein 
which has been found to be translocated from the plasma membrane to the 
nucleus for its function. The other best known example is Notch. Upon 
stimulation, Notch is cleaved by γ-secretase and its cytoplasmic domain, 
Notch intracellular domain (NICD), is translocated from the cell membrane to 
the nucleus. NICD has been shown to contain a nuclear localization sequence 
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(NLS), which facilitates the nuclear localization. NICD is able to modulate the 
transcriptional activity of the cells (Guruharsha et al., 2012). 
 
It is not sure whether translocation of cCD137L to nucleus involves a similar 
pathway as Notch signaling since no NLS has been identified in CD137L thus 
far. Nonetheless, cCD137L is a relatively small protein (~15kD, Dr. Moh Mei 
Chung, personal communication) therefore it might not be a transcription 
factor and interact directly with DNA. However, cCD137L might be capable 
of modulating transcription through the interaction with other nuclear proteins 
or nuclear factors. 
 
4.4 Limitations 
One of the most significant limitations of this study is that all of the 
experiments are performed using cell lines and in vitro. Although there are 
plenty of relevant correlations of this study to the clinical observations of HL, 
a confirmation in an in vivo system would be desirable. The main obstacle for 
performing in vivo experiments is the lacking of proper animal models. Many 
groups have tried to xenotransplant HL cell lines into immunocompromised 
mice (Dewan et al., 2005), but the usages of these models is often limited to 
drug testing and are not suitable for this current study, as the interaction of 
HRS cells with a "human" microenvironment is necessary. An alternative to 
the immunocompromised mice is to establish a humanized mouse model but 
this will be both technically challenging and time consuming. 
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On the other hand, this study addresses the effect of CD137 on HL in a 
collective manner without considering the effect of CD137 in each individual 
subtype of HL. As detailed in the Introduction, different HL subtypes have 
distinct pathological features and these variations might cause a different 
involvement of the ectopically expressed CD137 in the pathogenesis of a 
particular HL subtype. For example in the lymphocyte depleted subtype of HL, 
histiocytes are the predominant infiltrating cells that surround HRS cells. The 
abundance of histiocytes might affect the downregulation of CD137L simply 
because the CD137L expressed by the histiocytes in the microenvironment is 
likely to outnumber the CD137 expressed by HRS cells. Therefore, it is 
possible that the ectopic CD137 expression might have different effects on 
each HL subtype. Therefore, further characterization of CD137 in each HL 
subtype should be performed. 
 
4.5 Future works 
In this current study, a novel mechanism which is used by HRS cells to escape 
host immunity has been described. This finding provides an insight which 
could be useful for understanding the pathogenesis of other malignancies and 
autoimmune diseases or for developing a more effective immunotherapy for 
HL patients. Here, I would like to discuss a few potential future projects which 
will further strengthen the hypothesis in this study, and other potential 
branches resulting from this work which might be equally important. 
 
First, the CD137 induced downregulation of CD137L should be confirmed in 
vivo. However, there is currently no suitable animal model for Hodgkin 
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lymphoma as mentioned earlier. Although generation of a Hodgkin lymphoma 
model using NOG (NOD/Shi-scid/IL-2Rγnull) mice has been reported earlier, 
the reproducibility of this murine model is unknown and might be unsuitable 
for our future works (Dewan et al., 2005). Hence the easier and more realistic 
alternative is to observe the effect of CD137 in primary HL lesions from HL 
patients. We should be able to observe the colocalization of CD137 and 
CD137L in HRS cells and more importantly, to verify the downregulation of 
CD137L in the HL microenvironment. 
 
CD137 expressed on HRS cells is functional and the possibility that it may be 
inducing signal into HRS cells has been shown. In this study, a coated anti 
CD137 antibody (clone JG1.6a) has been shown to induce morphological 
changes of HRS cells. However, the signaling mechanism leading to these 
morphological changes are still unknown. Hence, it is worth to investigate the 
advantages HRS cells acquire by this potential CD137 signalling. Does 
CD137 signalling play a role in the constitutive activation of NF-κB in cells? 
The effect of CD137 signalling on the proliferation and viability of HRS cells 
should also be investigated. 
 
Ectopic CD137 expression was also found in other cancers like Follicular DC 
cancer, T cell lymphoma and osteosarcoma. Hence, it is important to 
characterize the effects of ectopically expressed CD137 on these cancers. 
Besides that, it is also important to confirm whether the ectopic CD137 
expression leads to a similar immune escape mechanism in these cancers as 
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the one identified in HL. The new knowledge will lead to a better 
understanding of the pathogenesis of these malignant diseases. 
 
As suggested in the previous section, intercellular CD137 trogocytosis and 
CD137L downregulation is unlikely to be a mechanism solely used by HL for 
their survival. This mechanism is more likely involved in CD137-CD137L 
regulation under normal physiological conditions as well. Hence, the transfer 
of CD137 and CD137L downregulation should be confirmed in primary cells. 
For example, the transfer of CD137 from activated T cells to APC and its 
functional consequences should be demonstrated. 
 
Last but not least, the ultimate goal of this study is to make use of the current 
knowledge to improve the clinical outcome of patients. A neutralizing 
antibody might be useful to neutralize CD137 on HRS cells, and hence, 
enhance the elimination of HRS cells. However, the concern is that the anti-
CD137 neutralizing antibody might also be distributed through the blood 
stream and cause a systemic neutralization of CD137. This might eventually 
lead to the decrease of T cell and NK cell activity in patients, and worsen their 
condition. In order to overcome this issue, an anti-CD30/anti-CD137 bi-
specific antibody can be developed. The bi-specific antibody will have a 
higher affinity towards CD30+ CD137+ HRS cells, than towards cells 
expressing only CD137 or CD30 on their cell surface. By adjusting the titre of 
the bi-specific antibody, we propose that it can specifically target HRS cells 




In this study, the effects of ectopic CD137 expression on survival of HRS cells 
have been elucidated. Ectopic CD137 expression has been shown to 
downregulate the expression of CD137L in both HRS cells and their 
surrounding cells which leads to a decreased T cell activity. CD137L 
downregulation is caused by interaction of CD137L with CD137 and the 
formation of a CD137-CD137L complex. This complex is then removed from 
the cell surface via endocytosis. 
This study has described a new immune escape mechanism used by HRS cells 
for their survival advantage of HRS cells which will be important for the 
understanding of the pathogenesis of HL, and potentially the pathogenesis of 
other malignant diseases as well. In addition, this study also suggests a new 
regulatory mechanism of CD137 and CD137L that could be important in 
modulating immune responses in both a normal and a disease state. 
 
Nonetheless, further studies are required to understand the involvement of the 
identified mechanism in vivo and under physiological condition, and whether 
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APPENDIX I ACRYLAMIDE GEL CASTING 
 
For making of 10 ml of resolving gel: 
Reagent (ml) 8% gel 10% gel 12% gel 15% gel 
MilliQ water 4.6 4.0 3.3 2.3 
30% Acrylamide mix (Bio-rad) 2.7 3.3 4.0 5.0 
1.5M Tris (pH 8.8) 2.5 2.5 2.5 2.5 
10% SDS (1st Base) 0.1 0.1 0.1 0.1 
10% APS (Sigma-Aldrich) 0.1 0.1 0.1 0.1 





For making of 2 ml of stacking gel: 
 
Reagent (ml)  
MilliQ water 1.4 
30% Acrylamide mix (Bio-rad) 0.33 
1.5M Tris (pH 6.8) 0.25 
10% SDS (1st Base) 0.02 
10% APS (Sigma-Aldrich) 0.02 





APPENDIX II MEDIA AND BUFFERS 
 
1. Cell culture 
RPMI with 10% FBS 
For preparing of 1 L: 
Item Quantity Source 
RPMI-1640 16.4 g Sigma-Aldrich 
L-glutamine (200 mM) 10 ml Gibco 
Sodium bicarbonate 2 g Sigma-Aldrich 
FBS 100 ml Biowest 
MilliQ water Top up to 1 L - 
 




RPMI, 10% FBS with Penicillin and streptomycin 
For preparing of 100 ml:  
Item Quantity Source 
RPMI with 10% FBS 99 ml - 
Penicillin (10,0000 U) 




Selective medium (5 µg/ml Blasticidin) 
For preparing of 100 ml:  
Item Quantity Source 
RPMI with 10% FBS 99.5 ml - 
Blasticidin (1 mg/ml) 500 µl Sigma-Aldrich 
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Cell line freezing medium (20% FBS, 10% DMSO) 
For preparing of 100 ml: 
Item Quantity Source 
RPMI with 10% FBS 77.8 ml - 
FBS 12.2 ml Biowest 
DMSO 10 ml Sigma-Aldrich 
 
 
Primary cell freezing medium, Part A (40% FBS)  
For preparing of 100 ml:  
Item Quantity Source 
RPMI with 10% FBS 66.7 ml - 
FBS 33.3 ml Biowest 
 
 
Primary cell freezing medium, Part B (40% FBS, 20% DMSO)  
For preparing of 100 ml:  
Item Quantity Source 
RPMI with 10% FBS 44.4 ml - 
FBS 35.6 ml Biowest 







2. PBMC isolation and purification 
10 x Phosphate buffer saline (PBS) 
For preparing of 1 L: 
Item Quantity Source 
Sodium chloride (NaCl) 80 g Sigma-Aldrich 
Potassium chloride 
(KCl) 2 g Sigma-Aldrich 
Disodium hydrogen 
phosphate (Na2HPO4) 14.4 g Sigma-Aldrich 
Monopotassium 
phosphate (KH2PO4) 2.4 g Sigma-Aldrich 
MilliQ water Top up to 1 L - 
 
Adjusted to pH 7.4. 
 
 
1 x PBS  
For preparing of 1 L:  
Item Quantity Source 
10 x PBS 100 ml - 
MilliQ water Top up to 1 L - 
 
Sterilized with autoclaving. 
 
PBS with 2 mM EDTA 
For preparing of 100 ml:  
Item Quantity Source 
1 x PBS 99.6 ml - 
EDTA (0.5 M) 400 µl 1st Base 
 
Sterilized with autoclaving. 
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RBC lysis buffer 
For preparing of 1 L:  
Item Quantity Source 
Ammonium chloride 
(NH4Cl) 8.29 g Sigma-Aldrich 
Sodium bicarbonate 
(NaHCO3) 0.84 g Sigma-Aldrich 
EDTA (0.5 M) 23 ml 1st Base 
MilliQ water Top up to 1 L - 
 
Filtered with 0.22 µm filter unit (Nalgene). 
 
MASC buffer 
For preparing of 1 L:  
Item Quantity Source 
10 x PBS 100 ml - 
Bovine serum albumin 
(BSA) 5 g Science Werke 
EDTA (0.5 M) 4 ml 1st Base 
MilliQ water Top up to 1 L - 
 









3. Flow cytometry 
FACS buffer  
For preparing of 500 ml:  
Item Quantity Source 
10 x PBS 50 ml - 
FBS 2.5 ml Biowest 
20% Sodium azide 500 µl Sigma-Aldrich 




PBS with 0.05% Tween-20 (PBST) 
For preparing of 1 L:  
Item Quantity Source 
10 x PBS 100 ml - 
Tween-20 500 µl NUMI store, NUS 
MilliQ water Top up to 1 L - 
 









5. Co-Immunoprecipitation and Western blot 
RIPA buffer 
For preparing of 100 ml:  
Item Quantity Source 
Tris 606 mg 1st Base 
NaCl 876 mg NUMI store, NUS 
SDS (10% w/v) 1 ml 1st Base 
Sodium deoxycholate 0.5 µg Sigma-Aldrich 
Triton-X 1 ml Bio-Rad 
PMSF (100mM) 1 ml*                                    Sigma-Aldrich 
MilliQ water Top up to 100 ml - 
 
Stirred until dissolve and adjusted to pH 7.4. *PMSF was added prior to use. 
 
Non-denaturing lysis buffer (PBS with 1 % Triton-X) 
For preparing of 100 ml:  
Item Quantity Source 
1 x PBS 98 ml - 
Triton-X 1 ml Bio-Rad 
PMSF (100mM) 1 ml*                                    Sigma-Aldrich 
 






5 x Tris-Glycine SDS Running Buffer 
For preparing of 1 L:  
Item Quantity Source 
Tris 15.1 g 1st Base 
Glycine 72 g 1st Base 
SDS (10% w/v) 50 ml                                   1st Base 
MilliQ water Top up to 1 L - 
 
Stirred until dissolve. 
 
1 x Tris-Glycine SDS Running Buffer  
For preparing of 1 L:  
Item Quantity Source 
5 x Tris-Glycine Buffer 200 ml - 




For preparing of 1 L:  
Item Quantity Source 
Tris 3.02 g 1st Base 
Glycine 14.4 g 1st Base 
Absolute Ethanol 200 ml                                   NUMI store, NUS 
MilliQ water Top up to 1 L - 
 
Stirred until dissolve and adjusted to pH 8.0. 
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Western blot blocking buffer 
For preparing of 100 ml:  
Item Quantity Source 
Skim milk powder 5 g Anlene 
PBST Top up to 100 ml - 
 
Stirred until dissolve. 
 
6. Confocal microscopy 
Fixing buffer (4% PFA in PBS) 
For preparing of 100 ml:  
Item Quantity Source 
1 x PBS 100 ml - 
Paraformaldehyde (PFA) 4 g Sigma-Aldrich 
 
5 M sodium hydroxide (NaOH) was added dropwise until PFA was fully 
dissolved. Then adjusted to pH 7.2 with hydrochloric acid (HCl). 
 
Permeabilization buffer (0.2% Triton-X in PBS)  
For preparing of 100 ml:  
Item Quantity Source 
1 x PBS 100 ml - 
Triton-X 200 µl Bio-Rad 
 





Antigen Clone Company Usage Dilution Figure 
CD137 4B4-1-PE BD Pharmigen Flow cytometry staining 1:10 4-6 
 BBK-2 Lab Vision CD137 neutralization 1:200 7-9, 14, 15, 17, 20 
   Flow cytometry staining 1:200 9, 20, 23-28 
   Co-immunoprecipitation 2 µg/1 mg of protein 16, 17 
   Confocal staining 1:100 18 
 JG1.6a Novus Biologicals CD137 stimulation 1:200 31, 32 
CD137L 5F4-PE Biolegend Flow cytometry staining 1:10 9, 10, 20 
   Confocal staining 1:10 18 
 5F4 Biolegend CD137L neutralization 1:100 10, 11 
      
      
      










 41B436 Adipogen CD137L neutralization 1:200 10, 11 
   Western blot 1:2000 14-17, 29 
   Flow cytometry staining 1:200 23-26 
 C65-485 BD Pharmigen CD137L neutralization 1:100 10, 11 
 EPR1172Y Origene Confocal staining  33 
CD11b ICRF44 eBioscience Flow cytometry staining  1:10 27 










APPENDIX IV CD137L DOWNREGULATION ON 

















CD137L expression on monocytes and B cells following co-culture with 
HRS cell lines 
5 x 105 cells/ml of KM-H2 or HDLM-2 cells were co-cultured with 106 of 
PBMC suboptimally activated with 1 ng/ml of anti-CD3 (Clone Okt3). 24 h 
later, the cells were harvested and stained for CD137L (clone 41B436), 
CD11b (for monocytes) and CD20 (for B cells), and analyzed with flow 
cytometry. The histograms shown are gated on (A) CD11b+ or (B) CD20+ 
population only. Open histograms show the PBMC alone condition, while 
grey histogram show PBMC co-culture with HRS cells condition. The 



















































CD137L expression on monocytes and B cells following co-culture with 
HRS cell lines 
5 x 105 cells/ml of KM-H2 or HDLM-2 cells were co-cultured with 106 of 
PBMC suboptimally activated with 1 ng/ml of anti-CD3 (Clone Okt3). 24 h 
later, the cells were harvested and stained for CD137L (clone 41B436), 
CD11b (for monocytes) and CD20 (for B cells), and analyzed with flow 
cytometry. The histograms shown are gated on (A) CD11b+ or (B) CD20+ 
population only. Open histograms show the isotype staining of CD137L. The 







































CD137L expression on monocytes and B cells following co-culture with 
HRS cell lines 
5 x 105 cells/ml of KM-H2 or HDLM-2 cells were co-cultured with 106 of 
PBMC suboptimally activated with 1 ng/ml of anti-CD3 (Clone Okt3). 24 h 
later, the cells were harvested and stained for CD137L (clone 41B436), 
CD11b (for monocytes) and CD20 (for B cells), and analyzed with flow 
cytometry. The histograms shown are gated on (A) CD11b+ or (B) CD20+ 
population only. Open histograms show the isotype staining of CD137L. The 
percentages of positively stained cells are shown in the histograms.  
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